Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Share Name	Share Symbol	Market	Type
Panacea Life Sciences Holdings Inc (PK)	USOTC:PLSH	OTCMarkets	Common Stock

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	0.00	0.00%	0.061	0.0611	0.10				0.00	13:01:47

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: June 30, 2023

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____________ to _____________

Commission File Number: 001-38190

Panacea Life Sciences Holdings, Inc.

(Exact name of registrant as specified in its charter)

Nevada		27-1085858
(State or another jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

5910 S University Blvd, C18-193, Greenwood Village, CO 80121

(Address of principal executive offices, Zip Code)

800-985-0515

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
N/A		N/A		N/A

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large, accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large, accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

	Large Accelerated Filer ☐	Accelerated Filer ☐
	Non-Accelerated Filer ☒	Smaller reporting company ☒
		Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

State the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 17,645,352 shares of common stock, par value $0.0001 per share, outstanding as August 2, 2023.

TABLE OF CONTENTS

		Page

	PART I – FINANCIAL INFORMATION
Item 1.	Financial Statements	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	21
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	27
Item 4.	Controls and Procedures	27

	PART II – OTHER INFORMATION

Item 1.	Legal Proceedings	28
Item 1A.	Risk Factors	28
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	29
Item 3.	Defaults Upon Senior Securities	29
Item 4.	Mine Safety Disclosures	29
Item 5.	Other Information	29
Item 6.	Exhibits	29
	Signatures	30

PART I. FINANCIAL INFORMATION

ITEM 1. Financial Statements.

Panacea Life Sciences Holdings, Inc. and Subsidiary

Unaudited Condensed Consolidated Balance Sheets

	June 30, 2023			December 31, 2022
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	8,190		$	6,951
Accounts receivable, net		272,090			206,127
Other receivables, related party		500,000			500,000
Inventory		4,357,733			4,448,725
Marketable securities related party		460,388			1,107,362
Prepaid expenses and other current assets		149,295			113,098
TOTAL CURRENT ASSETS		5,747,696			6,382,263

Operating lease right-of-use asset, net, related party		3,062,090			3,242,381
Property and equipment, net		6,855,283			7,675,995
Goodwill		2,188,810			2,188,810
TOTAL ASSETS	$	17,853,879		$	19,489,449

LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES:
Accounts payable and accrued expenses	$	3,677,546		$	2,666,076
Operating lease liability, current portion, related party		2,325,808			2,090,271
Note payable-current, related party		10,829,779			9,871,803
Convertible note payable, net		115,000			346,671
Paycheck protection loan, SBA Loan		99,100			99,100
TOTAL CURRENT LIABILITIES:		17,047,233			15,073,921

Operating lease liability, long-term portion, related party		2,800,766			2,987,208
Other long-term liabilities, related party		3,572,864			3,572,864
TOTAL LIABILITIES		23,420,863			21,633,993

Commitments and contingencies		-			-

STOCKHOLDERS’ EQUITY
Series A Preferred Stock: $0.0001 Par Value, 1,000 shares designated; 0 and 350 shares issued and outstanding on June 30, 2023 and December 31, 2022 respectively.		-			-
Series B-1 Preferred: $0.0001 Par Value, 32,000,000 shares designated; 1,500,000 and 1,500,000 shares issued and outstanding on June 30, 2023 and December 31, 2022 respectively.		150			150
Series B-2 Preferred: $0.0001 Par Value, 6,000,000 shares designated; 6,000,000 and 6,000,000 shares issued and outstanding on June 30, 2023 and December 31, 2022 respectively.		600			600
Series C Preferred: $0.0001 Par Value, 1,000,000 shares designated; 1,000,000 and 1,000,000 shares issued and outstanding on June 30, 2023 and December 31, 2022 respectively.		100			100
Series C-1 Preferred: $0.0001 Par Value, 10,000 shares designated and 10,000 and 10,000 shares issued and outstanding on June 30, 2023 and December 31, 2022 respectively.		1			1
Series C-2 Preferred: $0.0001 Par Value, 100 and 0 shares designated and 100 and 0 shares issued and outstanding on June 30, 2023 and December 31, 2022 respectively.		-			-
Series D Preferred: $0.0001 Par Value, 10,000 shares designated and 10,000 and 10,000 shares issued and outstanding on June 30, 2023 and December 31, 2022 respectively.		1			1
Preferred Stock, Value
Common Stock: $0.0001 Par Value, 650,000,000 shares authorized; 17,645,352 and 14,965,317 shares issued and outstanding on June 30, 2023 and December 31, 2022 respectively.		1,765			1,497
Additional paid in capital		23,993,533			23,760,704
Accumulated deficit		(29,563,134	)		(25,907,597	)
TOTAL STOCKHOLDERS’ EQUITY		(5,566,984	)		(2,144,544	)

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	17,853,879		$	19,489,449

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Panacea Life Sciences Holdings, Inc. and Subsidiary

Unaudited Condensed Consolidated Statements of Operations

	2023			2022			2023			2022
	Three Months Ended June 30,						Six Months Ended June 30,
	2023			2022			2023			2022
REVENUE		399,128		$	469,472		$	1,076,609		$	935,946
COST OF SALES		196,314			331,500			648,186			697,591
GROSS PROFIT		202,814			137,972			428,423			238,355

OPERATING EXPENSES
Production related operating expenses		1,131,711			1,173,296			2,399,870			2,461,111
General and administrative expenses		145,213			204,678			392,626			665,230
TOTAL OPERATING EXPENSES		1,276,924			1,377,974			2,792,496			3,126,341

LOSS FROM OPERATIONS		(1,074,110	)		(1,240,002	)		(2,364,073	)		(2,887,986	)

OTHER INCOME (EXPENSES)
Interest expense		(366,944	)		(569,985	)		(747,101	)		(1,071,280	)
Unrealized gain (loss) on marketable securities, net		(464,719	)		(260,273	)		(646,974	)		(1,205,077	)
Realized gain on sale of securities		-			22,816			-			22,816
Other income (loss)		-			27,598			-			27,598
Employer retention credit		-			-			-			253,791
Rental Income		41,531			58,045			101,863			116,091
Gain on extinguishment of debt		-			-			748			-
TOTAL OTHER INCOME (EXPENSE)		(790,132	)		(721,799	)		(1,291,464	)		(1,856,061	)

INCOME (LOSS) BEFORE INCOME TAXES		(1,864,242	)		(1,961,801	)		(3,655,537	)		(4,744,047	)

TAXES		-			-			-			-

NET INCOME (LOSS)		(1,864,242	)	$	(1,961,801	)	$	(3,655,537	)	$	(4,744,047	)

Per-share data
Basic and diluted loss per share		(0.11	)	$	(0.13	)	$	(0.21	)	$	(0.32	)

Weighted average number of common shares outstanding		17,645,352			14,965,317			17,645,352			14,965,317

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

PANACEA LIFE SCIENCES HOLDINGS, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY

(unaudited)


	Six Months Ended June 30, 2023
	Preferred Stock				Common Stock				Additional Paid-in			Accumulated			Total Stockholder’s
	Shares		Amount		Shares		Amount		Capital			Deficit			Equity
Balance as of December 31, 2022		8,530,000	$	853		14,965,317	$	1,497	$	23,760,704		$	(25,907,597	)	$	(2,144,544	)
Sale of shares to investors		-		-		454,545		46		74,955						75,000
Issuance of common shares for services						275,490		28		23,069						23,097
Issuance of restricted shares to employees						1,410,000		141		(141	)					-
Shares issued in settlement of convertible note		-		-		540,000		54		134,946						135,000
Net Loss		-		-		-		-		-			(3,655,537	)		(3,655,537	)
Balance as of June 30, 2023		8,530,000	$	853		17,645,352	$	1,765	$	23,993,532		$	(29,563,134	)	$	(5,566,984	)

	Three Months Ended June 30, 2023
	Preferred Stock				Common Stock				Additional Paid-in			Accumulated			Total Stockholder’s
	Shares		Amount		Shares		Amount		Capital			Deficit			Equity
Balance as of March 31, 2023		8,530,350	$	853		15,505,317	$	1,550	$	23,895,650		$	(27,698,892	)	$	(3,800,839	)
Sale of shares to investors		-		-		454,545		46		74,955						75,000
Issuance of common shares for services		-		-		275,490		28		23,069						23,097
Issuance of restricted shares to employees				-		1,410,000		141		(141	)					-
Net Income (Loss)		-		-		-		-					(1,864,242	)		(1,864,242	)
Balance as of June 30, 2023		8,530,000	$	853		17,645,352	$	1,765	$	23,993,532		$	(29,563,134	)	$	(5,566,984	)

The accompanying notes are an integral part of these financial statements

	Six Months Ended June 30, 2022
	Preferred Stock					Common Stock				Additional Paid-in			Accumulated			Total Stockholder’s
	Shares			Amount		Shares		Amount		Capital			Deficit			Equity
Balance as of December 31, 2021		8,530,350		$	853		14,073,708	$	1,407	$	23,865,155		$	(16,765,013	)	$	7,102,402
Shares issued in respect of the merger		-			-		834,331		83		(83	)		-			-
Issuance of common shares for services							57,278		6		54,994						55,000
Conversion of Series A Preferred to convertible debt and warrants		(350	)								(159,362	)					(159,362	)
Net Loss		-			-		-		-		-			(4,744,047	)		(4,744,047	)
Balance as of June 30, 2022		8,530,000		$	853		14,965,317	$	1,497	$	23,760,704		$	(21,509,060	)	$	2,253,993

	Three Months Ended June 30, 2022
	Preferred Stock				Common Stock				Additional Paid-in			Accumulated			Total Stockholder’s
	Shares		Amount		Shares		Amount		Capital			Deficit			Equity
Balance as of March 31, 2022		8,530,000	$	853		14,762,342	$	1,476	$	23,725,724		$	(19,547,259	)	$	4,180,794
Shares issued for acquisition		-		-		154,637		15		(15	)		-			-
Issuance of common shares for services						48,338		5		34,955						35,000
Net Income (Loss)		-		-		-		-		-			(1,961,801	)		(1,961,801	)
Balance as of June 30, 2022		8,530,000	$	853		14,965,317	$	1,497	$	23,760,704		$	(21,509,060	)	$	2,253,993

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

Panacea Life Sciences, Inc.

Statements of Cash Flows

	2023			2022
	Six Months Ended June 30,
	2023			2022
Cash flows from operating activities
Net income (loss)	$	(3,655,537	)	$	(4,744,047	)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation		845,282			818,586
Realized gain on sale of securities		-			(22,816	)
Unrealized (gain)/loss on marketable securities		646,974			1,205,077
Non cash settlement of convertible note and accrued interest		74,999			-
Amortization of intangible assets		-			30,700
Amortization of debt discount and non-cash interest expense		38,329			568,219
Changes in operating assets and liabilities
Accounts receivable		(65,963	)		24,945
Inventory		90,992			(216,202	)
Prepaid expense and other assets		(36,197	)		(41,823	)
Accounts payable and accrued expenses		1,034,568			982,474
Operating lease liability, net		229,386			229,387
Net cash used in operating activities		(797,167	)		(1,165,500	)

Cash flows from investing activities
Proceeds from sale of marketable securities		-			46,832
Net fixed asset acquisitions		(24,570	)		(17,604	)
Net Cash provided by (used in) investing activities		(24,570	)		29,228

Cash flows from financing activities
Repayment of notes payable		(135,000	)		-
Payments of principal on notes payable		(118,000	)		(540,848	)
Proceeds from Notes payable - related party		1,075,976			1,693,875
Cash provided by financing activities		822,976			1,153,027

Net increase (decrease) in Cash and Cash Equivalents		1,239			16,755
Cash and Cash Equivalents, Beginning of Period		6,951			19,774
Cash and Cash Equivalents, End of Period	$	8,190		$	36,529

Supplemental Disclosure of Cash Flow Information
Cash paid for income taxes during the year	$	-		$	-
Interest payments during the year	$	-		$	-

Noncash investing and financing activity
Conversion of Preferred A shares to Note Payable	$	-		$	385,000
Issuance of Common Stock for services	$	-		$	55,000
Capitalized assets purchased on account - related party	$	-		$	168,578

The accompanying notes are an integral part of these financial statements.

PANACEA LIFE SCIENCES HOLDINGS, INC. AND SUBSIDIARY

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2023

NOTE 1 - NATURE OF ORGANIZATION

Organization and Business Description

PANACEA LIFE SCIENCES HOLDINGS, Inc. (the “Company”, “we”, “us”, “our”) was incorporated on January 18, 2008, in the State of Nevada. In January 2019, the Company added to the scope of its business activities, efforts to produce, market and sell products made from industrial hemp containing cannabidiol (“CBD”). On June 30, 2021, the Company entered into a Securities Exchange Agreement (the “Exchange Agreement”) with Panacea Life Sciences, Inc., (“Panacea”) a seed to sale cannabinoid company and with the stockholders of Panacea. Pursuant to the Exchange Agreement, the former Panacea stockholders assumed majority control of the Company and all operations are now operated by Panacea, which as a result of the share exchange, became a wholly owned subsidiary of the Company. In October 2021, the Company changed its name from Exactus Inc. to Panacea Life Sciences Holdings, Inc.

Panacea Life Sciences Holdings, Inc. (PLSH) is currently a holding company structured to develop and facilitate manufacturing, research, product development and distribution in the high-growth, natural human and animal health and wellness market segment. Its subsidiary, Panacea Life Sciences, Inc. (PLS) is a woman-founded and led company dedicated to manufacturing, distribution, research and production of the highest-quality nutraceutical, cannabinoid, mushroom, kratom and other natural, plant-based ingredients and products. PLS operates out of a 51,000 square foot, state-of-the-art, cGMP facility in Golden, Colorado. PLS was founded by Leslie Buttorff in 2017 as a woman-owned business, was formed to own and engage in creating disruptive healthcare and veterinary natural relief products to make a difference in the lives of humans and pets.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation and principles of consolidation

The Company’s consolidated financial statements include the financial statements of Panacea Life Sciences, Inc., a wholly owned subsidiary acquired on June 30, 2021.

The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America and the rules and regulations of the United States Securities and Exchange Commission (the “SEC”) for interim financial information, which includes consolidated unaudited interim financial statements and present the consolidated unaudited interim financial statements of the Company and its wholly-owned subsidiary as of June 30, 2023. Accordingly, they do not include all of the information and notes required by accounting principles generally accepted in the United States of America. All intercompany transactions and balances have been eliminated. In the opinion of management, all adjustments necessary to present fairly our financial position, results of operations, stockholders’ equity and cash flows as of June 30, 2023, and 2022, and for the periods then ended, have been made. Those adjustments consist of normal and recurring adjustments. Operating results for the three ended June 30, 2023 and 2022 are not necessarily indicative of the results that may be expected for any subsequent quarters or for the year ending December 31, 2023. Certain information and note disclosures normally included in our annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted.

Going concern

These unaudited condensed consolidated financial statements are presented on the basis that the Company will continue as a going concern. Panacea has combined with Panacea Life Sciences Holdings, Inc. (formerly Exactus), so the below items reflect the consolidated company. The going concern concept contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Since our inception in later 2017, we have generated losses from operations. As of June 30, 2023, our accumulated deficit was $29.6 million, and we had $0.465 million in cash and liquid stock. As of June 30, 2023, the shares of common stock we hold in 22^nd Century Group, Inc. (1,188,000 shares) (Nasdaq: XXII) (“XXII”) was valued at approximately $0.457 million. The XXII stock is pledged to secure a $4.063 million promissory note in favor of J&N Real Estate (“J&N”) and a $1.624 million promissory note in favor of Leslie Buttorff, CEO of the Company. J&N is owned by the CEO. These items are shown on the balance sheet as related party loans. These factors raise doubt about the Company’s ability to continue as a going concern for a period of 12 months from the issuance date of this report. Management cannot provide assurance that the Company will ultimately achieve or maintain profitable operations or become cash flow positive or raise additional debt and/or equity capital. In addition, due to insufficient revenue, we will need to obtain further funding through public or private equity offerings, debt financing, collaboration arrangements or other sources in order to maintain active business operations. We currently do not have sufficient cash flow to pay our ongoing financial obligations on a consistent basis. The issuance of any additional shares of Common Stock, preferred stock or convertible securities could be substantially dilutive to our shareholders. In addition, adequate additional funding may not be available to us on acceptable terms, or at all. These unaudited condensed consolidated financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Use of Estimates

The Unaudited Condensed Consolidated Financial Statements have been prepared in conformity with US GAAP and required management of the Company to make estimates and assumptions in preparation of these statements. Actual results may differ significantly from those estimates. Significant estimates made by management include but are not limited to the useful life of property and equipment, incremental borrowing rate used in the calculation of right of use asset and lease liability, reserves for inventory, allowance for doubtful accounts, revenue allocations, valuation allowance on deferred tax assets, assumptions used in assessing impairment of long-term assets, assumptions used in the calculation of net realizable value of inventory and fair value of non-cash equity transactions.

Cash and Cash Equivalents

For purposes of balance sheet presentation and reporting of cash flows, the Company considers all unrestricted demand deposits, money market funds and highly liquid debt instruments with an original maturity of less than 90 days to be cash and cash equivalents. There were no cash equivalents. The Company places its cash and cash equivalents with high-quality financial institutions. At times, balances in the Company’s cash accounts may exceed the Federal Deposit Insurance Corporation (“FDIC”) limit. On June 30, 2023, the Company’s cash balances did not exceed the FDIC limit.

Accounts Receivable

Accounts receivable are generally unsecured. The Company establishes an allowance for doubtful accounts receivable based on the age of outstanding invoices and management’s evaluation of collectability. Accounts are written off after all reasonable collection efforts have been exhausted and management concludes that likelihood of collection is remote. Any future recoveries are applied against the allowance for doubtful accounts. An allowance of $10,000 was taken at the beginning of 2022 to allow for any doubtful accounts to be expensed. As of June 30, 2023, none of this allowance was expensed. The Company’s accounts receivable policy changed in 2021 to only provide larger, well-established companies with Net 30 payment terms. For all other sales they are paid by credit card or wires received before the product is shipped to the customer.

Inventory

Inventories are stated at low of cost or net realizable value. Inventories of purchased materials are valuated using a moving average method and managed by first in first out basis (FIFO). Inventories of internally manufactured materials are valuated using a standard costing method and are also managed on a FIFO basis. Production related costs that are capitalized as inventory as part of the standard cost valuation include the direct materials consumed, direct labor used, indirect labor used, and manufacturing overhead. Overhead is calculated based on specific manufacturing process and allocated on an order-by-order basis. Production variances that occur between standard cost valuation and actual costs are expensed as incurred in the income statement as part of cost of goods sold.

Marketable securities

The Company’s marketable securities consists of 1,188,000 shares of XXII which are classified as available-for-sale and included in current assets as they are pledged to secure two promissory notes (see Note 2 – Going Concern). Securities are valued based on market prices for identical assets using third party certified pricing sources. Available-for-sale securities are carried at fair value with unrealized and realized gains and losses reported as a component of income (loss). Realized gains and losses, if any, are calculated on the specific identification method and are included in other income in the condensed consolidated statements of operations.

Fair Value Measurements

The Company adopted the provisions of Accounting Standard Codification (“ASC”) Topic 820, “Fair Value Measurements and Disclosures”, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value, and expands disclosure of fair value measurements. The guidance prioritizes the inputs used in measuring fair value and establishes a three-tier value hierarchy that distinguishes among the following:

	●	Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.

	●	Level 2—Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly.

	●	Level 3—Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

The following table shows, by level within the fair value hierarchy, the Company’s assets and liabilities at fair value on a recurring basis as of June 30, 2023, and December 31, 2022:

	June 30, 2023								December 31, 2022
	Total		Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3
Marketable securities	$	460,388	$	460,388	$	-		-	$	1,107,362	$	1,107,362	$	-	$	-
Total	$	460,388	$	460,388	$	-	$	-	$	1,107,362	$	1,107,362	$	-	$	-

The following table is a schedule of the Company’s marketable securities. The following table is schedule of the Company’s marketable securities:

SCHEDULE OF MARKETABLE SECURITIES

	June 30, 2023
Balance at beginning of year	$	1,107,362
Unrealized loss on marketable securities, net		(646,974	)
Balance at end of period	$	460,388

As of June 30, 2023, the Company has no liabilities that are re-measured at fair value.

Property and Equipment

Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method on the various asset classes over their estimated useful lives, which range from 3 to 10 years when placed in service. The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income in the year of disposition.

Intangible Assets and Goodwill

The Company has intangible assets. Goodwill is comprised of the purchase price of business combinations in excess of the fair market value assigned at acquisition to the tangible and intangible assets acquired. Goodwill is not amortized. The Company tests goodwill for impairment on an annual basis. The Company performed its most recent goodwill impairment using a discounted cash flow analysis and found that the fair value exceeded the carrying value. It has $2.189 million of goodwill from the acquisition of the assets of Phoenix Life Sciences, Inc. (“Phoenix”) in October 2017 and intangible assets of $0.030 million as of June 30, 2023, and $0.061 million for as of December 31, 2022. In the acquisition of Phoenix, the Company acquired product formulas which is classified as an intangible asset.

The following table is a schedule of the Company’s intangible assets and goodwill:

		Estimated Life
Goodwill from Phoenix Acquisition		Tested Yearly for Impairment
Intangibles – Formulations		5 Years

		June 30, 2023				December 31, 2022
Goodwill		$	2,188,810			$	2,188,810

Leases

The Company determines if an arrangement is a lease at inception. Contracts containing a lease are further evaluated for classification as an operating or finance lease. In determining the leases classification, the Company assesses among other criteria: (i) 75% or more of the remaining economic life of the underlying asset is a major part of the remaining economic life of that underlying asset; and (ii) 90% or more of the fair value of the underlying asset comprises substantially all of the fair value of the underlying asset. Operating leases are included in operating lease right-of-use (“ROU”) assets, other current liabilities and long-term operating lease liabilities in the Company’s consolidated balance sheets. Finance leases are included in property, plant and equipment, net, other current liabilities, and long-term finance lease liabilities in the Company’s consolidated balance sheets. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. For leases with terms greater than 12 months, the Company records the ROU asset and liability at commencement date based on the present value of lease payments according to their term.

The Company uses incremental borrowing rates based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement date. The ROU asset also includes any lease payments made and excludes lease incentives. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expenses are recognized on a straight-line basis over the lease term or the useful life of the leased asset.

In addition, the carrying amount of the ROU and lease liabilities are remeasured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments or a change in the assessment to purchase the underlying asset.

Revenue Recognition

The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers.

The Company accounts for a contract when it has been approved and committed to, each party’s rights regarding the goods or services to be transferred have been identified, the payment terms have been identified, the contract has commercial substance, and collectability is probable. Revenue is generally recognized net of allowances for returns and any taxes collected from customers and subsequently remitted to governmental authorities. However, the Company’s sales are primarily through retail stores, purchase orders or ecommerce; thus, currently contract liabilities are negligible. The Company does not have any multiple-element arrangements.

Some of the Company’s contract liabilities consist of advance customer payments. Contract liability results from transactions in which the Company has been paid for products by customers, but for which all revenue recognition criteria have not yet been met. Once all revenue recognition criteria have been met, the contract liabilities are recognized. The Company recorded $330,499and $368,065 in advanced customer payments as of June 30, 2023, and December 31, 2022, respectively and these amounts are included in the balance sheet line item of accounts payable and accrued expenses.

The following table shows the Company’s advanced customer payments:

	June 30, 2023		December 31, 2022
Balance, beginning of period	$	368,065	$	24,585
Payments received for unearned revenue		214,498		412,891
Revenue earned		252,064		69,411

Balance, end of period	$	330,499	$	368,065

Revenue is recognized when a customer obtains control of promised goods or services and is recognized in an amount that reflects the consideration that an entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in exchange for those goods. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods in the contract; (ii) determination of whether the promised goods are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.

Revenue related to the sale of products is recognized once goods have been sold to the customer and the performance obligation has been completed. In both contracted purchase and retail sales, we offer consumer products through our online stores. Revenue is recognized when control of the goods is transferred to the customer. This generally occurs upon our delivery to a third-party carrier or, to the customer directly. Revenue from tolling services is recognized when the performance obligation, such as processing of the material, has been completed and output material has been transferred to the customer.

Revenue is generally recognized net of allowances for returns and any taxes collected from customers and subsequently remitted to governmental authorities. A contract liability results from transactions in which the Company has been paid for products by customers, but for which all revenue recognition criteria have not yet been met. Once all revenue recognition criteria have been met, the contract liabilities are recognized. The Company does not have any multiple-element arrangements.

The Company also has recorded other income related to rental income it receives from leasing out space in the laboratory it occupies.

Shipping and Handling Costs

The Company accounts for shipping and handling fees in accordance with ASC 606. The amounts charged to customers for shipping products are recognized as revenues and the related freight costs of shipping products are classified in general and administrative costs as incurred. Shipping costs are included as a component of general and administrative expenses and were $43,001 and $17,965 for the six months ended June 30, 2023, and 2022, respectively. Shipping costs were $32,633 and $3,782 for the three months ended June 30, 2023, and 2022, respectively.

Advertising & Marketing

Advertising costs are expensed when incurred and are included in advertising and promotional expense in the accompanying statements of operations. Included in this category are expenses related to public relations, investor relations, new package design, website design, design of promotional materials, cost of trade shows, cost of products given away as promotional samples, and paid advertising. The Company recorded advertising and marketing costs in general and administrative expenses and were $18,193 and $98,108 for the six months ended June 30, 2023, and 2022, respectively. Advertising and marketing costs were $14,563 and $31,312 for the three months ended June 30, 2023, and 2022, respectively.

Segment Information

The Company follows the provisions of ASC 280-10 Segment Reporting. This standard requires that companies disclose operating segments based on the manner in which management disaggregates the Company in making internal operating decisions. Segment identification and selection is consistent with the management structure used by the Company’s chief operating decision maker to evaluate performance and make decisions regarding resource allocation, as well as the materiality of financial results consistent with that structure. Based on the Company’s management structure and method of internal reporting, the Company has one operating segment. The Company’s chief operating decision maker does not review operating results on a disaggregated basis; rather, the chief operating decision maker reviews operating results on an aggregate basis.

Stock-Based Compensation

The Company accounts for its stock compensation under the ASC 718-10-30, Compensation - Stock Compensation using the fair value-based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period. This guidance establishes standards for the accounting for transactions in which an entity exchanges its equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity’s equity instruments or that may be settled by the issuance of those equity instruments.

The Company uses the Black-Scholes model for measuring the fair value of options and warrants. The stock based fair value compensation is determined as of the date of the grant or the date at which the performance of the services is completed (measurement date) and is recognized over the vesting periods. The Company recognizes forfeitures when they occur.

Earnings per Share

The Company computes basic and diluted earnings per share amounts in accordance with ASC Topic 260, “Earnings per Share”. Basic earnings per share is computed by dividing net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per share reflects the potential dilution that could occur if preferred stock converted to common stock and warrants are exercised. Preferred stock and warrants are excluded from the diluted earnings per share calculation if their effect is anti-dilutive.

The following financial instruments were not included in the diluted loss per share calculation for the six months ended June 30, 2023 and 2022 because their effect was anti-dilutive:

	2023		2022
	For the six months ended June 30,
	2023		2022
Options to purchase common stock		551,854		277,705
Warrants to purchase common stock		1,117,092		1,117,092
Series B-1 Convertible Preferred		6,679		6,679
Series B-2 Convertible Preferred		26,786		26,786
Series C Convertible Preferred		2,289,220		2,289,220
Series C-1 Convertible Preferred		1,064,908		1,064,908
Series D Convertible Preferred		1,628,126		1,628,126
Convertible Notes		-		-
Total		6,684,665		6,410,516

Income Taxes

Income taxes are accounted for under the asset and liability method prescribed by FASB ASC Topic 740. These standards require a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position. If the more likely than not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax asset will not be realized.

Recently Issued Accounting Standards

In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40), Accounting for Convertible Instruments and Contract’s in an Entity’s Own Equity. The ASU simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. The ASU simplifies the diluted net income per share calculation in certain areas. The ASU is effective for annual and interim periods beginning after December 31, 2021, and early adoption is permitted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company does not expect the adoption of ASU 2020-6 to have any material impact on its consolidated financial statements.

In May 2021, the Financial Accounting Standards Board (“FASB”) issued ASU 2021-04 “Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation— Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815- 40) Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options” which clarifies and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. An entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as follows: i) for a modification or an exchange that is a part of or directly related to a modification or an exchange of an existing debt instrument or line-of-credit or revolving-debt arrangements (hereinafter, referred to as a “debt” or “debt instrument”), as the difference between the fair value of the modified or exchanged written call option and the fair value of that written call option immediately before it is modified or exchanged; ii) for all other modifications or exchanges, as the excess, if any, of the fair value of the modified or exchanged written call option over the fair value of that written call option immediately before it is modified or exchanged. The amendments in this Update are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. The Company is currently evaluating the impact of this standard on its consolidated financial statements.

The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

NOTE 3 – PROPERTY, EQUIPMENT, NET OF ACCUMULATED DEPRECIATION

Property and equipment, net including any major improvements, are recorded at historical cost. The cost of repairs and maintenance is charged against operations as incurred. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets, generally as follows:

		Estimated Life
Computers and technological assets		3 – 5 Years
Furniture and fixtures		3 – 5 Years
Machinery and equipment		5 – 10 Years
Leasehold improvement		10 Years

Property and equipment, net consists of the following:

SCHEDULE OF PROPERTY AND EQUIPMENT

	June 30, 2023			December 31, 2022
Computers and technological assets	$	3,776,320		$	3,776,320
Furniture and fixtures		55,950			55,950
Machinery and equipment		7,790,036			7,765,466
Land		92,222			92,222
Leasehold improvements		1,508,915			1,508,915
Total		13,223,443			13,198,873
Less accumulated depreciation		(6,368,160	)		(5,522,878	)
Total property and equipment, net	$	6,855,283		$	7,675,995

Depreciation expenses for the three and six month periods ended June 30, 2023 and 2022 were $422,728, 845,282, and 409,895, $818,586 respectively.

NOTE 4 - INVENTORY

Inventory consists of the following components:

SCHEDULE OF INVENTORY

	June 30, 2023		December 31, 2022
Raw Materials	$	964,317	$	870,530
Semi-Finished		1,771,177		1,863,501
Finished Goods		1,598,280		1,694,574
Packaging		23,959		20,120
Trading				0
Total	$	4,357,733	$	4,448,725

Inventories are stated at lower of cost or net realizable value using the standard costing method for its work in process and finished goods. For its raw materials, trading goods, and packaging supplies, the Company utilizes the moving average method for costing purposes and FIFO. At this time there are no inventory reserves required. Inventory includes all of our various storage locations: including inventory held in our VICKI machines, other warehouses, and off-site trailers. It also includes inventory purchased for customer projects.

NOTE 5 –OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES – RELATED PARTY

Right of Use

The Company adopted Accounting Standards Update (“ASU”) No. 2016-02, “Leases” (“ASC 842”) on January 1, 2019, the start of our 2019 fiscal year. The Company has one lease arrangement with a related party entered into on December 22, 2018, for 3-year term starting with January 1, 2019 for certain laboratory facilities, with a nine-year extension option. This lease was extended and now expires on December 31, 2030. At inception, the Company recognized a Right of Use Asset and a corresponding lease liability in the amount of $4,595,509. The Company’s lease arrangements may contain both lease and non-lease components. The Company has elected to combine and account for lease and non-lease components as a single lease component. The Company has incorporated residual value obligations in leases for which there is such occurrences. Regarding short-term leases, ASC 842-10-25-2 permits an entity to make a policy election not to apply the recognition requirements of ASC 842 to Short-term leases. The Company has elected not to apply the ASC 842 recognition criteria to any leases that qualify as Short-Term Leases.

The Company leases a portion of the property (formerly the Environmental Protection Agency building) in Golden, CO from J&N Real Estate, owned by the CEO, a related party with a term expiring on December 31, 2030. The lease consists of all laboratory space including testing facilities, water treatment, extraction and production. The lease of the property is based on the fair market rent and triple net lease (NNN) values competitive in the marketplace for a cGMP facility. The Company also subleases some of its laboratory space to other CBD companies. This income is presented under the Other Income line items of the statements of operations. The leases vary from short-term monthly leases to 3-year leases but are all cancellable.

Below is a summary of our right of use assets and liabilities as of June 30, 2023, and December 31, 2022:

	June 30, 2023			December 31, 2022
Right-of-use assets	$	3,062,090		$	3,242,381

Present value of operating lease liabilities	$	3,168,620		$	3,347,331
Less: Long-term portion of operating lease liability		(2,800,766	)		(2,987,208	)
Short-term portion of operating lease liability		367,854			360,123
Unpaid balances		1,957,947			1,730,136
Total short-term lease liability obligations	$	2,325,801		$	2,090,259
Weighted-average remaining lease term (Ends December 31, 2030)		7.5 years			8 years

Weighted-average discount rate					3.0	%

During the three and six months ended June 30, 2023, and 2022, we recognized approximately $114,693 and $229,386 respectively in operating lease costs. Operating lease costs are included in operating expenses in our consolidated statement of operations.

Approximate future minimum lease payments for our right of use assets over the remaining lease periods as of June 30, 2023, are as follows:


2023		227,811
2024		460,178
2025		464,780
2026		469,427
2027		474,122
Thereafter		1,451,002
Total undiscounted operating lease payments		3,547,320
Less: Imputed interest		(378,700	)
Present value of operating lease liabilities	$	3,168,620

NOTE 6 – NOTES PAYABLE

Convertible Note Payable

On November 18, 2021, the Company entered into a Securities Purchase Agreement (“SPA”) with Lincoln Park Capital Fund, LLC (the “Purchaser”) pursuant to which the Company agreed to sell a 10% original issue discount senior convertible promissory note in the principal amount of $1,100,000 (the “Convertible Note”) and five-year warrants to purchase 785,715 shares of the Company’s common stock, par value $0.0001 per share at an exercise price of $1.40 per share (the “Warrants”) pursuant to the terms and conditions of the SPA for a total purchase price of $1,000,000. The Note was due November 18, 2022, which is one year from the issuance date and was paid.

The Warrants can be exercisable for a five-year term beginning on May 18, 2022, at an exercise price of $1.40 per share, subject to certain adjustments which are substantially similar to those contained in the Note, including the Qualified Offering adjustment. The Warrants contain a 4.99% beneficial ownership limitation pursuant to which neither may be converted or exercised, as applicable, if and to the extent that following such conversion or exercise the holder would beneficially own more than 4.99% of the Company’s outstanding common stock, subject to increase to 9.99% upon 61 days’ prior written notice by the holder.

On March 3, 2022, the Company entered into an Exchange Agreement (the “Agreement”) with an institutional investor (the “Investor”) pursuant to which the Company agreed to issue a 10% original issue discount senior convertible promissory note in the principal amount of $385,000 (the “Second Note”) and five-year warrants to purchase 275,000 shares of the Company’s common stock, par value $0.0001 per share at an exercise price of $1.40 per share (the “Warrants”) in exchange for 350 shares of the Company’s Series A Convertible Preferred Stock (“Series A”). The Second Note matures on March 3, 2023. The Agreement was entered into after the Investor exercised the most favored nations rights contained in Section 7(b) of the Company’s Certificate of Designation of Preferences, Rights and Limitations of the Series A in connection with the consummation of a private placement with the Purchaser on November 18, 2021. The warrant fair value of $190,638 and the original issue discount of $35,000 were treated as a discount to the Second Note and will be amortized over the term of the Second Note. Amortization of the debt discount for the three and six months ended June 30, 2023, was $0 and $17,309 and for the three and six months ended June 30, 2022, was $56,255 and $73,564 and were recorded as interest expense. The debt discount balance on June 30, 2023, fully amortized.

Paycheck Protection Program Funding U.S. Small Business Administration Loan

On May 28, 2020, the Company received a secured, 30-year, Economic Injury Disaster Loan in the amount of $99,100 from the U.S. Small Business Administration. The loan carries interest at a rate of 3.75% per year, requires monthly payments of principal and interest, and matures in 30 years. Installment payments, including principal and interest, of $483 monthly, will begin 12 months from the date of the promissory Note. The SBA loan is secured by a security interest in the Company’s tangible and intangible assets. The loan proceeds were used as working capital to alleviate economic injury caused by the Covid-19 disaster occurring in the month of January 31, 2020, and continuing thereafter. As of June 30, 2022, the current principal balance of this note amounted to $99,100 and accrued interest was approximately $2,047.

Notes payable – related party and other liability

As part of the Exchange Agreement certain loan balances (“J&N Loans) from J&N Real Estate Company, Inc., an affiliate of the Company’s CEO, (“J&N”) and historical interest owed of $1,932,358 were combined into a new promissory note with the principal amount of $4.062 million (“J&N Note”). The J&N Note bears annual interest at 12% and was secured by a pledge of certain XXII common stock owned by Panacea (See Note 2 Going concern).

On June 30, 2021, the Company issued its CEO, Ms. Buttorff, a 10% promissory note in the amount of $1,624,000 (the “Buttorff Note”). The Buttorff Note was secured by a pledge of certain XXII common stock owned by the Company (See Note 2 Going concern). This demand note replaced a prior working capital note that the Company had issued on January 1, 2021. On July 1, 2021, the Company issued Ms. Buttorff a 10%, $1 million line of credit note at 10% annual rate which Ms. Buttorff has increased that expired in January 2022, which Ms. Buttorff has extended (see Note 6 – Notes Payable – Buttorff Note). In June 2023, the Buttorff line of credit was increased to $5.5 million and is now due on January 31, 2025.

Below is a summary of our notes payable as of June 30, 2023 and December 31, 2022:

SCHEDULE OF NOTES PAYABLE RELATED PARTY

	June 30, 2023		December 31, 2022
J&N Note	$	4,062,713	$	4,062,713
CEO Notes (Initial note of $1,685,685 and line of credit)		6,767,066		5,809,090
Total related party notes	$	10,829,779	$	9,871,803

Other long-term liabilities, related party

The Company has recorded a related party liability (“Fixed Asset Loan”) in the amount of $3,059,474 as of June 30, 2023 and December 31, 2022, respectively, relating to SAP software and support fees which were paid by an affiliate company of the CEO. The balance bears interest of 6% and the maturity date has not yet been determined. The interest requirement of 6% ended as of December 31, 2022.

In 2020, the Company recorded an additional related party liability in the amount of $513,390 in respect to certain building improvements, due to J&N Real Estate Company (a company owned by the CEO) (“J&N Building Loan”). This balance bears no interest, and the maturity date has not yet been determined.

SCHEDULE OF NOTES PAYABLE

	June 30, 2023		December 31, 2022
Other long-term liabilities, related party
Fixed Asset Loan	$	3,059,474	$	3,059,474
J&N Building Loan		513,390		513,390
Total	$	3,572,864	$	3,572,864

NOTE 7 - STOCKHOLDERS’ EQUITY

Common stock

The Company’s authorized common stock consists of 650,000,000 shares with a par value of $0.0001 per share.

During both the three and six months ended June 30, 2023, the Company issued 730,035 shares of common stock in respect of the share exchange effected in 2021. The Company issued 275,490 shares to vendors and 454,545 shares to investors that contributed funds to the Company. The issuance of the shares was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933 and Rule 506(b) promulgated thereunder.

Common stock options

Stock Option Plan

On June 30, 2021, the Company’s stockholders approved the 2021 Equity Incentive Plan (the “2021 Plan”). The 2021 Plan provided for the issuance of 4,049,409 incentive awards in the form of non-qualified and incentive stock options, restricted stock awards, restricted stock unit awards, warrants and preferred stock. The awards may be granted by the Company’s Board of Directors to its employees, directors and officers and to consultants, agents, advisors and independent contractors who provide services to the Company or to a subsidiary of the Company. The exercise price for stock options must not be less than the fair market value of the underlying shares on the date of grant. The incentive awards shall either be fully vested and exercisable from the date of grant or shall vest and become exercisable in such installments as the Board of Directors or Compensation Committee may specify. Stock options expire no later than ten years from the date of grant. Unless sooner terminated, the Plan shall terminate in 10 years. This plan had 346,854

fully vested options and a total of 551,854 allocated.

Stock Options

A summary of the stock option activity is presented below:

SCHEDULE OF STOCK OPTIONS

	Options Outstanding as of June 30, 2023
					Weighted
	Number of		Weighted		Average
	Shares		Average		Remaining
	Subject		Exercise		Contractual		Aggregate
	to		Price Per		Life		Intrinsic
	Options		Share		(in years)		Value

Balance on December 31, 2022		346,854	$	2.80		3.57	$	-
Options granted		205,000		0.21		-		-
Options exercised		-		-		-		-
Options canceled / expired		-		-		-		-
Balance at June 30, 2023		551,854	$	1.84		2.94	$	-

Vested and exercisable on June 30, 2023		551,854	$	1.84		2.94	$	-

Stock Warrants

On March 3, 2022, the Company entered in an Exchange Agreement with an institutional investor pursuant to which the Company issued a 10% original issue discount senior convertible promissory note in the principal amount of $385,000 (the “Note”) and five-year warrants to purchase 275,000 shares of the Company’s common stock, par value $0.0001 per share at an exercise price of $1.40 per share in exchange for 350 shares of the Company’s Series A Convertible Preferred Stock.

As of June 30, 2023, the Company also had outstanding warrants to purchase an aggregate of 56,377 shares of common stock. These warrants were previously issued by the Company prior to the exchange agreement.

The Company’s outstanding warrants as of June 30, 2023, are summarized as follows, and all were exercisable at that date.

SCHEDULE OF WARRANTS OUTSTANDING

	Warrants Outstanding as of June 30, 2023
					Weighted
	Number of		Weighted		Average
	Shares		Average		Remaining
	Subject		Exercise		Contractual		Aggregate
	to		Price Per		Life		Intrinsic
	Warrants		Share		(in years)		Value

Balance on December 31, 2022		1,117,092	$	2.02		4.05		-
Warrants granted		-		-		-		-
Warrants exercised		-		-		-		-
Warrants canceled / expired		-		-		-		-
Balance on June 30, 2023		1,117,092	$	2.02		3.56	$	-

Vested and exercisable on June 30, 2023		1,117,092	$	2.02		3.56	$	-

As of June 30, 2022, the outstanding warrants have no intrinsic value.

Restricted Stock

During both the three and six months ended June 30, 2023, the Company issued 1,685,490 shares of the Company’s common stock to various employees and directors of the Company. A summary of the restricted stock activity is presented below:

SUMMARY OF RESTRICTED STOCK

Restricted Stock

Common Stock

Balance on December 31, 2022

107,993

Balance on June 30, 2023

1,793,483

As of June 30, 2023, there were no unamortized or unvested stock-based compensation costs related to restricted share arrangements.

Preferred Stock

The Company’s authorized preferred stock consists of 50,000,000 shares with a par value of $0.0001. There are no new activities related to preferred stock.

NOTE 8 - COMMITMENTS AND CONTINGENCIES

Legal Matters

In the ordinary course of business, the Company enters into agreements with third parties that include indemnification provisions which, in its judgment, are normal and customary for companies in the Company’s industry sector. These agreements are typically with business partners, and suppliers. Pursuant to these agreements, the Company generally agrees to indemnify, hold harmless, and reimburse indemnified parties for losses suffered or incurred by the indemnified parties with respect to the Company’s products, use of such products, or other actions taken or omitted by us. The maximum potential number of future payments the Company could be required to make under these indemnification provisions is unlimited.

On February 1, 2023, Plaintiff filed Plaintiffs Original Petition (“Petition”) in a lawsuit against the Panacea Defendants related to the Purchase Order, styled Knock-Out Specialties, Inc. v. Panacea Life Sciences, LLC, Leslie Buttorff, and Ben Doucette, Cause No. 380- 00849-2023, in the 380th District Court of Collin County, Texas. On March 20, 2023, the Panacea Defendants removed the State Lawsuit to the United States District Court for the Eastern District of Texas, Sherman Division in Case No. 4:23- cv-00217. On March 27, 2023, the Panacea Defendants filed their Motion to Dismiss and Brief in Support. This matter was settled in July 2023 and the result is the Company will pay the Plaintiff $80,000.

Concentrations

The Company has no contingencies, material commitments, or purchase obligations or sales obligations.

On the revenue side, in the three months ended June 30, 2023, we have a concentration of two customers. Both are contract manufacturing customers who represent 41% and 15% of revenue. In the six months ended June 30, 2023, there is a concentration of three customers. All are contract manufacturing customers, and represent 12%, 17%, and 20% of revenue.

The other concentration is in the accounts receivable category, where three customer accounts for 69% of the accounts receivable. One of the three customer contracts is unique in that we produced all of the products for them to sell, and they pay Panacea as the items are sold in the ecommerce marketplace. Thus, until their inventory is depleted, we will have accounts receivable. This customer receivable is 23% of the 69%.

NOTE 9 - RELATED PARTY TRANSACTIONS

Notes Payable and Accrued Interest – Related Parties

For information on related party loans to the Company and other related party transactions, see Notes 5 and 6, Operating Lease and Notes Payable.

The accrued interest and interest expenses recorded for related party loans are shown below.

	June 30, 2023		December 31, 2022
Accrued Interest
Related party loan- J&N Real Estate	$	1,095,854	$	796,891
Related party loan-CEO loan		371,510		271,585
Related party loan – Line of credit		592,752		282,869
Accrued Interest		592,752		282,869

	Three months ended		Six months ended		Three months ended		Six months ended
	June 30, 2023		June 30, 2023		June 30, 2022		June 30, 2022
Interest Expense
Related party loan- J&N Real Estate	$	151,713	$	298,964	$	134,637	$	265,315
Related party loan-CEO loan		50,584		99,925		45,790		90,453
Related party loan – Line of Credit		164,646		309,883		51,700		81,835
Interest Expense		164,646		309,883		51,700		81,835

Other

The Company continues to hold 1,188,000 shares of XXII stock which is available for sale.

NOTE 10– SUBSEQUENT EVENTS

On July 10, 2023, PLSH announced it had entered into agreements to acquire eight retail locations in the Tampa, Florida area, offering Kava, Kratom, VAPE and CBD products and beverages operating as Nitro Kava & Kratom, including inventory, equipment and recipes, distribution facilities and a warehouse located in Largo, Florida, generating $2.9 million of annual revenues (unaudited) for the fiscal year ended December 31, 2022.

On August 1, 2023, PLSH announced it has entered into a Letter of Intent with Melodial Global Health (ASX:ME1)(formerly Creso Pharma) to acquire Sierra Sage Herbs (“Sierra”), maker of the best-selling Green Goo, Southern Butter and Good Goo natural products and Halucenex, a company researching novel psychedelic compounds. The deal would extend Panacea’s footprint into natural first aid and body care products and establishes a strong tie with Melodial through a significant stock ownership stake.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

Business Overview

The Company is a Nevada corporation organized in 2008. The Company has pursued opportunities in Cannabidiol, which we refer to as “CBD”, since December 2018 when we expanded our focus to pursue opportunities in hemp-derived CBD. Effective October 25, 2021, we changed our name to Panacea Life Sciences Holdings, Inc. To that end, on June 30, 2021 we entered into the Exchange Agreement with Panacea and the Panacea stockholders and as a result became a seed-to-sale CBD company. The former Panacea stockholders have assumed majority control of the Company, and all our operations are now operated through Panacea which because of the share exchange became a wholly-owned subsidiary of the Company. Leslie Buttorff, who became the Company’s Chief Executive Officer and a director upon the closing of the share exchange, also became our principal stockholder through common stock and Convertible Preferred Stock issued to her and entities she controls.

PLSH is structured to develop and facilitate manufacturing, research, product development and distribution in the high-growth, natural human and animal health & wellness market segment. The company is dedicated to manufacturing, distribution, research and production of the highest-quality nutraceutical, cannabinoid, mushroom, kratom and other natural, plant-based ingredients and products. PLS operates out of a 51,000 square foot, state-of-the-art, cGMP facility in Golden, Colorado. As of June 30, 2023, Panacea sells over 40 different product SKUs of CBD and CBG products.

We believe that our competitive advantages are derived from being vertically integrated that allows for extraction, e

enrichment and manufacturing under a cGMP quality environment: 1) Using pharmaceutical formulation methods to optimize the delivery of various hemp products, 2) Developing both full spectrum and THC-free products, 3) Hemp supply, and 4) utilize Good Manufacturing Practice to produce goods that are safe and quality products that deliver consistent dosing. The cannabinoids have also been reported to treat human disease conditions where currently multiple pharmacologicals are needed to address, e.g., Post Traumatic Stress Disorder (PTSD), or where there is no current cure such as Alzheimer’s, Parkinson’s Disease, and age-related dementia, to name a few. Although numerous reports describe cannabis/hemp extract health benefits the industry lacks sufficient clinical data and quality control to provide patient benefit. We are combining human and pet clinical studies with Good Manufacturing Process manufacturing to generate a panel of products. Our products are formulated with delivery methods for health benefits including an intellectual property portfolio enabling development of topical creams, sublinguals, oral soft gel capsules, patches, and sprays. Our products are derived from organic practices industrial hemp grown in Colorado.

Our goal is to be a leader in wholesale and retail sales channels for end-products, such as nutraceuticals, supplements and pet and farm products. As government regulation of CBD and related products becomes more lenient in certain jurisdictions, and other barriers to entry decline, we anticipate experiencing an increase in competition and an intensifying competitive environment, including potentially the introduction of new seed-to-sale companies and/or the expansion of operations by current competitors. Further, numerous other factors are expected to be critical to our ability to be and remain competitive in our business and goals, including product quality and prices, brand strength, production and distribution capabilities and geographic scope of operations and market presence. Additionally, market conditions can shift demand for CBD products, such as competitive pricing, the effects of inflation, regulatory changes and economic or geopolitical turmoil.

In later 2022 we shifted our focus to the nutraceutical industry and to date we have closed over 35 different manufacturing contracts. We offer “white label” licensing to retail businesses and contract manufacturing services to smaller CBD companies and softgel manufacturing to nutraceutical companies. This shift was required as the CBD industry slowed given the FDA’s inaction and we were well suited to use our excess manufacturing equipment.

Panacea intends to position itself to provide a comprehensive menu of natural and organic health and wellness products catering to all segments of the health and wellness minded community, while supporting research into important medical and health challenges, such as the effects of CBD/CBG/psilocybin on conditions such as irritable bowel syndrome, pain management, brain injury and PTSD. We hope to capture significant market share in the three categories of mushroom products under development — functional, amanita and psilocybin — while enhancing our on-going research efforts at Colorado State University at the Panacea Cannabinoid Lab in order to produce valuable information about these emerging compounds.

Partnership with Universities

The grand opening of the Panacea Life Sciences Cannabinoid Research Center at Colorado State University was held on October 19, 2021. The first studies at the center are underway for isolation of rare cannabinoids, examining cannabidiol’s effects on Inflammatory Bowel Disease (IBS), canine and human dementia, as well as supporting research into chronic pelvic pain.

Company Information Technology Infrastructure

The ERPCannabis system is based on an SAP architecture and was used to develop the base installation. All financial, human resource, payroll, procurement, production planning and materials management business processes are represented in this system. In addition, the system is linked to our e-Commerce website www.panacealife.com. This system allows us to update product costing and determine inventory levels which will be critical as the company expands. In addition, sophisticated financial and payroll processing are inherent in the solution; thus, offering investors detailed accounting results related to company investments. We plan to expand on the use of this infrastructure for acquisitions and service offerings.

Results of Operations

Set forth below is the discussion of the results of operations of the Company for the three months ended June 30, 2023, compared to the three months ended June 30, 2022. The information which follows relates to the operations of Panacea which under applicable accounting rules are treated as the operation of the Company.

On February 23 and 24, 2023, the Golden area experienced extreme below zero temperatures which cause major damages in the laboratory. To date, we are still dealing with issues related to temperature controls and equipment problems. Insurance companies have been slow to address these required repair costs. We hope to have these all resolved and repaired by year end.

Three Months Ended June 30, 2023, and 2022

Net Revenues

Our primary focus in the last two quarters has been in manufacturing products for nutraceutical companies. We are still engaged in the business of producing and selling products made from industrial hemp. Revenue consists of sales to nutraceutical companies, sales of our brand CBD and CBG products, white label and contract manufacturing sales to other CBD companies, raw material sales (distillate and isolate), tolling products, and leasing space.

Our revenues for the three months ended June 30, 2023, decreased by $70,344, or 15%, to $399,128 as compared to $469,472 for the three months ended June 30, 2022. The decrease in sales was due to larger manufacturing contracts that were not completed by the end of the period, but will be recorded in the 3^rd Q. The decrease is also due to certain projects that were delayed due to extreme heat in our production wing due to the insurance companies’ delaying equipment repairs.

Cost of Sales

Cost of sales for the three months ended June 30, 2023, decreased by $135,186 or 41% to $196,314 as compared to $331,500 for the three months ended June 30, 2023. The decrease in cost of sales was due to several larger scale projects where ingredients have not been fully consumed. And the corresponding decrease in revenues due to the building temperature issues.

Operating Expenses

Operating expenses for the three months ended June 30, 2023, decreased by $101,049, or 7%, to $1,276,925 as compared to $1,377,974 for the three months ended June 30, 2023. This is due to decreases in general and administrative expenses.

Production related operating expenses for the three months ended June 30, 2023, decreased by $41,584 or 4% to $1,131,712 as compared to $1,173,294 during the three months ended June 30, 2023. The decrease in production related operating expenses is primarily due to lower building operational costs.

General and administrative expenses for the three months ended June 30, 2023, decreased by $59,465, or 29%, to $145,213 as compared to $204,680 during the three months ended June 30, 2023. The decrease in general and administrative costs is primarily due to decreased sales and advertising costs.

Other income (expense)

Other income for the three months ended June 30, 2023, decreased by $68,332 or 9% to ($790,131) as compared to ($721,799) for the three months ended June 30, 2023. The decrease in other income is primarily due to the unrealized loss of XXII’s marketable securities held.

Six Months Ended June 30, 2023 and 2022

Net Revenues

Our revenues for the six months ended June 30, 2023, increased by $140,663, or 15%, to $1,076,609 as compared to $935,946 for the six months ended June 30, 2022. The increase in sales in 2023 was due primarily to our refocus on using our manufacturing equipment to produce products for numerous nutraceutical companies.

Cost of Sales

Cost of sales for the six months ended June 30, 2023, decreased by $49,405, or 7% to $648,186 as compared to $697,591 for the six months ended June 30, 2023. The decrease in cost of sales was due primarily to several larger scale projects where ingredients have not been fully consumed.

Operating Expenses

Operating expenses for the six months ended June 30, 2023, decreased by $333,844, or 11%, to $2,792,497 as compared to $3,126,341for the six months ended June 30, 2023. This is due to decreases in both operating expenses and general and administrative expenses.

Production related operating expenses for the six months ended June 30, 2023, decreased by $ 61,240, or 2%, to $2,399,871 as compared to $2,461,111 during the six months ended June 30, 2023. The decrease in production related operating expenses is primarily due to decreased building operational costs.

General and administrative expenses for the six months ended June 30, 2023, decreased by $272,604, or 41%, to $392,626 as compared to $665,230 during the six months ended June 30, 2023. The decrease in general and administrative costs is primarily due to decreased sales and advertising costs.

Other income (expense)

Other income for the six months ended June 30, 2023, increased by $564,598 or 30% to ($1,291,463) as compared to ($1,856,061) as compared to $2,920,984 for the six months ended June 30, 2023. The increase in other income is primarily due to lower interest expense.

Liquidity and Capital Resources

Cash flows from operating activities

The largest source of operating cash is from our customers. Our white label and contract manufacturing customers pay before the products are released and this now makes up the majority of our revenue. Some larger customers have either net 10-, 2%- or 30-day net terms. Our customers purchase CBD on-line, so credit card payments are collected and paid within 1-2 business days. Net cash used in operating activities was $797,167 and $1,165,501 for six months ended June 30 for 2023 and 2022, respectively. Approximately $1.9 million of our $3.7 million net loss in 2023 was non-cash.

Cash flows from investing activities

Cash outlay for the acquisition of fixed assets comprised the majority of this category and were $24,570 and $29,229 for the six months ended June 30, 2023, and 2022, respectively.

Cash flows from financing activities

Net cash provided by financing activities for the six months ended June 30, 2023, was $822,976. For the same period in 2022 the financing was $1,153,027. In both years the primary financing was cash provided by Company’s CEO. In 2022 there was a cash payment received of $253,791 from the paycheck loan program.

As of August 2, 2023, we had $ 468,578 in cash and liquid stock of XXII. The Chief Executive Officer of the Company holds the XXII shares pursuant to the pledge agreement and has the power at any time to permit the Company to sell the shares to provide working capital. Panacea has borrowed substantial sums from Leslie Buttorff, our Chief Executive Officer, to meet its working capital obligations. As of June 30, 2021, Panacea owed an affiliate of Ms. Buttorff a 12% demand promissory note for $4.063 million and also held a 10% demand promissory note for $1.624 million secured by a pledge of certain XXII common stock owned by Panacea. On July 1, 2021, the Company issued a $1 million line of credit note at 10% annual rate, which Ms. Buttorff has extended to January 2024 and increased the line of credit to $5.5 million.

We do not have sufficient cash resources to sustain our operations for the next 12 months, particularly if the large sales agreements and purchase orders we have do not result in the revenue anticipated. We may be dependent on obtaining financing from one or more debt or equity offerings or further loans from Ms. Buttorff assuming she agrees to advance further funds.

These unaudited condensed consolidated financial statements are presented on the basis that the Company will continue as a going concern. The going concern concept contemplates the realization of assets and satisfaction of liabilities in the normal course of business. No adjustment has been made to the carrying amount and classification of the Company’s assets and the carrying amount of its liabilities based on the going concern uncertainty. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of 12 months from the issuance date of this report. Management cannot provide assurance that the Company will ultimately achieve profitable operations or become cash flow positive or raise additional debt and/or equity capital. In addition, due to insufficient revenue, we will need to obtain further funding through public or private equity offerings, debt financing, collaboration arrangements or other sources in order to maintain active business operations. We currently do not have sufficient cash flow to pay our ongoing financial obligations on a consistent basis. The issuance of any additional shares of common stock, preferred stock or convertible securities could be substantially dilutive to our stockholders. In addition, adequate additional funding may not be available to us on acceptable terms, or at all. If we are unable to raise capital, we will be forced to borrow additional sums from our Chief Executive Officer or delay, reduce or eliminate our research and development programs, we may not be able to continue as a going concern, and we may be forced to discontinue operations. These unaudited condensed consolidated financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Off Balance Sheet Arrangements

As of June 30, 2023, we had no material off-balance sheet arrangements.

Potential Impacts of Certain Current and Proposed Regulations on Our Business and Operations

Recently, a bill titled the Cannabis Administration and Opportunity Act, put forward by Senate Majority leader Chuck Schumer, D-NY, would amend the definition of a dietary supplement to remove the prohibition on marketing CBD as a dietary supplement. Management sees the bill, if enacted, as an opportunity for the FDA to accelerate their decision to classify CBD products as a dietary supplement. This would be a significant step for hemp/CBD companies as it would open the door to new selling opportunities, such as getting into retail stores, who have largely been hesitant to welcome CBD in their doors without a clear position from the FDA.

Many people are increasingly turning to CBD products for several reasons: CBD is non-psychoactive, so it does not produce a “high” like THC, there are few known contraindications, the properties of different cannabinoids can positively affect a wide range of ailments, and cannabinoids work directly and indirectly with the body’s endocannabinoid system to create balance known as homeostasis. As demand increases, we believe the FDA must provide more clarity about CBD’s legalization, and this bill is a promising first step.

For now, many companies that produce hemp-derived CBD products including Panacea undertake to abide by the same regulations as any other dietary supplements like ingredient filings, good manufacturing practices (GMP), and labeling and marketing provisions. Panacea will continue to sell CBD and other hemp-derived products while still awaiting a clear path from the FDA about how CBD products can be marketed and used.

Cautionary Statement Regarding Forward-Looking Statements

This quarterly report on Form 10-Q (this “Report”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the effectiveness of our products, studies regarding the long term effects of COVID-19, future studies that we may conduct , our operations in the hemp industry through Panacea, our expected revenue growth, proposed federal legislation and its potential impact on the CBD industry, our business relationship with XXII, our plans to raise capital, and our liquidity. Words such as “expects,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “could,” “would,” “may,” “intends,” “targets” and similar expressions or variations of such words are intended to identify forward-looking statements but are not the exclusive means of identifying forward-looking statements in this Report. The identification of certain statements as “forward-looking” is not intended to mean that other statements not specifically identified are not forward-looking. All statements other than statements about historical facts are statements that could be deemed forward-looking statements, including, but not limited to, statements that relate to our future revenue, product development, customer demand, market acceptance, growth rate, competitiveness, gross margins, and expenditures.

Although forward-looking statements in this Report reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by us. Further information on the risks and uncertainties affecting our business is contained in our filings with the SEC, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2022. We undertake no obligation to publicly update or revise any forward-looking statements, whether as the result of new information, future events or otherwise. Such risks, uncertainties and changes in condition, significance, value, and effect could cause our actual results to differ materially from those expressed herein and in ways not readily foreseeable. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Report and are based on information currently and reasonably known to us. We undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date of this Report, other than as required by law. Readers are urged to carefully review and consider the various disclosures made in this Report, which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects.

Critical Accounting Estimates and New Accounting Pronouncements

New Accounting Pronouncements

See Note 2, SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES to the unaudited condensed consolidated financial statements contained in Part I, Item 1 of this amendment No. 1 to the Quarterly Report on Form 10-Q.

Critical Accounting Estimates

The discussion and analysis of the Company’s financial condition and results of operations is based upon the Company’s condensed consolidated financial statements, which have been prepared in accordance with US GAAP. The preparation of the Company’s condensed consolidated financial statements requires its management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses and related disclosures. The Company’s management bases its estimates, assumptions and judgments on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Different assumptions and judgments would change the estimates used in the preparation of the Company’s condensed consolidated financial statements which, in turn, could change the results from those reported. In addition, actual results may differ from these estimates and such differences could be material to the Company’s financial position and results of operations.

Critical accounting estimates are those that the Company’s management considers the most important to the portrayal of the Company’s financial condition and results of operations because they require management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. The Company’s critical accounting estimates in relation to its condensed consolidated financial statements include those related to:

	●	Goodwill and intangible assets
	●	Fair value of marketable securities
	●	Incremental Borrowing Rate used Right of Use Asset Calculations
	●	Business combinations

Goodwill and Indefinite-Lived Intangibles

We allocate the cost of acquired companies to the identifiable tangible and intangible assets acquired and liabilities assumed, with the remaining amount classified as goodwill. The identification and valuation of these intangible assets and the determination of the estimated useful lives at the time of acquisition, as well as the completion of impairment tests, require significant management judgments and estimates. These estimates are made based on, among other factors, review of projected future operating results and business plans, economic projections, anticipated highest and best use of future cash flows and the cost of capital. The use of alternative estimates and assumptions could increase or decrease the estimated fair value of goodwill and other intangible assets, and potentially result in a different impact to our results of operations. Further, changes in business strategy and/or market conditions may significantly impact these judgments and thereby impact the fair value of these assets, which could result in an impairment of the goodwill or intangible assets.

Goodwill is not amortized but is tested for impairment annually and whenever events or circumstances change that indicate impairment may have occurred. We tested goodwill for impairment and determined there was no impairment and found not impairment charge based on the excess of a reporting unit’s carrying amount over our fair value.

Fair value of marketable securities

Marketable securities are recorded at fair value using the quoted market prices and changes in fair value are recorded as net realized gains or losses in comprehensive income. We monitor these investments for impairment and make appropriate reductions in carrying values as necessary.

Incremental Borrowing Rate used Right of Use Asset Calculations

We determine if a contract is a lease or contains a lease at the inception of the contract and reassess that conclusion if the contract is modified. All leases are assessed for classification as an operating lease or a finance lease. Operating lease right-of-use, or ROU, assets are included in non-current other assets on our consolidated balance sheet. Operating lease liabilities are separated into a current portion, included within other accrued liabilities on our consolidated balance sheet, and a non-current portion, included within other long-term liabilities on our consolidated balance sheet. We do not have any finance lease ROU assets or liabilities. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. We do not obtain and control the right to use the identified asset until the lease commencement date.

Our lease liabilities are recognized at the applicable lease commencement date based on the present value of the lease payments required to be paid over the lease term. Because the interest rate implicit in the lease is not readily determinable, we generally use our incremental borrowing rate to discount the lease payments to present value. The estimated incremental borrowing rate is derived from information available at the lease commencement date. We factor in publicly available data for instruments with similar characteristics when calculating our incremental borrowing rates. Our ROU assets are also recognized at the applicable lease commencement date. The ROU asset equals the carrying amount of the related lease liability, adjusted for any lease payments made prior to lease commencement and lease incentives provided by the lessor. Variable lease payments are expensed as incurred and do not factor into the measurement of the applicable ROU asset or lease liability.

Business Combinations

We have applied significant estimates and judgments in order to determine the fair value of the identified assets acquired, liabilities assumed, and goodwill recognized in connection with our business combinations to ensure the value of the assets and liabilities acquired are recognized at fair value as of the acquisition date. In measuring the fair value, we utilize valuation techniques consistent with the market approach, income approach, or cost approach.

The valuation of the identifiable assets and liabilities includes assumptions made in performing the valuation, such as projected revenue, weighted average cost of capital, discount rates, estimated useful lives, and other relevant assessments. These assessments can be significantly affected by our estimates, judgments, and assumptions. If actual results are not consistent with our estimates, judgments, or assumptions, or if additional or new information arises in the future that affects our fair value estimates, then adjustments to our initial fair value estimates may have a material impact to our purchase accounting or our results of operations. If actual results are not consistent with our estimates, judgments, or assumptions, or if additional or new information arises in the future, beyond our one-year measurement period, that affects our fair value estimates, then adjustments to our initial fair value estimates may have a material impact to our results of operations.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

A smaller reporting company is not required to provide the information required by this Item.

ITEM 4. CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures

Our management carried out an evaluation, with the participation of our Principal Executive Officer (who also now serves as our Principal Financial Officer), required by Rule 13a-15 or 15d-15 of the Securities Exchange Act of 1934 (the “Exchange Act”) of the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) or 15d-15(e) under the Exchange Act. Based on their evaluation, our Principal Executive Officer (who also now serves as our Principal Financial Officer) concluded that our disclosure controls and procedures are effective as of the end of the period covered by this report to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and is accumulated and communicated to our management, including our Principal Executive Officer and Principal Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

For the year-ended December 31, 2021, our Principal Executive Officer (who also now serves as our Principal Financial Officer) concluded that our disclosure controls and procedures were ineffective as of the end of that period. Since then, the Company has implemented three primary types of accounting controls that fall into categories of detection, preventive and corrective controls. These allow us to maintain effective controls for our financial reports. Using our ERP SAP system many accounting controls are already configured such as segregation of duties, independent user IDs and passwords and bank reconciliations. Other trial balance checks are completed within the system. In addition, monthly inventory and asset reconciliations are completed. Standard Operating Procedures are used throughout the organization, not only in the financial areas, but in all areas to maintain our GMP certifications for manufacturing. As a result, we believe that we have remediated the underlying issues.

Except as noted above, there were no changes in our internal control over financial reporting as defined in Rule 13a-15(f) or 15d-15(f) under the Exchange Act that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

From time–to-time, we may become involved in legal proceedings arising in the ordinary course of business. We are unable to predict the outcome of any such matters or the ultimate legal and financial liability, and at this time cannot reasonably estimate the possible loss or gain or range of loss/gain and accordingly have not accrued a related liability.

We filed suit in District Court in and for Osage, County, Oklahoma on December 19, 2019. We have sued Defendants, Mike Fisher, in his official capacity as Osage County District Attorney ex rel. State of Oklahoma as an investigating and/or prosecuting body, Eddie Virden in his official capacity as the Sheriff of the City of Osage as holder of the property, and the City of Pawhuska as the property seizing body, (collectively the “Government Defendants”) for the return of approximately 17,000 pounds of industrial hemp (the “Property”). We believe we were entitled to possession of the Property pursuant to an August 23, 2018, contract between us and Blue Circle Development, LLC (“BCD”), wherein we agreed to pay, and BCD agreed to deliver the Property according to certain terms. Plaintiff performed pursuant to the contract and is entitled to possession of the Property. We believe the Government Defendants wrongfully detained the Property and is responsible for damages to the Property and to us. On or about May 4, 2020, the Government Defendants improperly released the Property to BCD in violation of a Court Order. We have asserted claims against the Government Defendants for interference with the Court Order and BCD for improperly intercepting the Property from us. The case completed most of the discovery phase including document production and depositions. The parties will complete the discovery phase, potentially engage in dispositive motion briefing, and proceed toward a trial date. The damages claim is over $3.4 million. There is no assurance that we will be successful in our efforts related to this lawsuit or if we are, which amounts we will be able to recover.

ITEM 1A. RISK FACTORS.

We desire to take advantage of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Accordingly, we incorporate by reference the risk factors disclosed in Part I, Item 1A of our 2022 10-K.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES OR USE OF PROCEEDS.

During the three and six months ended June 30, 2023, the Company issued 1,410,000 shares of the Company’s common stock to various employees and directors of the Company 275,490 shares to vendors and 454,545 shares to investors that contributed funds to the Company. The issuance of the shares was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933 and Rule 506(b) promulgated thereunder.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. MINE SAFETY DISCLOSURES.

Not applicable.

ITEM 5. OTHER INFORMATION.

None.

ITEM 6. EXHIBITS.

		Incorporated by Reference			Filed or Furnished
Exhibit #	Exhibit Description	Form	Date	Number	Herewith
3.1	Amended Articles of Incorporation	8-K	7/7/21	3.1
3.1(a)	Certificate of Amendment to its Amended and Restated Articles of Incorporation – name change and reverse stock split	8-K	10/29/21	3.1
3.2	Amended and Restated Bylaws	10-K	3/31/22	3.2
3.4	Certificate of Designation for Series B-1 Preferred Stock	8-K	3/4/16	3.1
3.5	Certificate of Designation for Series B-2 Preferred Stock	8-K/A	2/17/16	3.2
3.6	Certificate of Designation for Series C Preferred Stock	10-Q	8/23/21	3.7
3.7	Certificate of Designation for Series C-1 Preferred Stock	10-Q	8/23/21	3.8
3.8	Certificate of Designation for Series C-2 Preferred Stock	8-K	10/29/21	3.2
3.9	Certificate of Designation for Series D Preferred Stock	10-Q	8/23/21	3.9
31.1	Certification of Principal Executive Officer and Principal Financial Officer (302)				Filed
32.1	Certification of Principal Executive and Principal Financial Officer (906)				Furnished***
101.INS	Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH	Inline XBRL Taxonomy Extension Schema Document				Filed
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document				Filed
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document				Filed
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document				Filed
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document				Filed
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

*** This exhibit is being furnished rather than filed and shall not be deemed incorporated by reference into any filing, in accordance with Item 601 of Regulation S-K.

Copies of this report (including the financial statements) and any of the exhibits referred to above will be furnished at no cost to our shareholders who make a written request to Panacea Life Sciences Holdings, Inc., at the address on the cover page of this report, Attention: Corporate Secretary.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Panacea Life Sciences Holdings, Inc.

August 15, 2023	/s/ Leslie Buttorff
	Leslie Buttorff
	Chief Executive Officer

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

AND PRINCIPAL FINANCIAL OFFICER

I, Leslie Buttorff, certify that:

1. I have reviewed this Form 10-Q of Panacea Life Sciences Holdings, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 15, 2023

/s/ Leslie Buttorff
Leslie Buttorff
Chief Executive Officer and Chief Financial Officer
(Principal Executive Officer and Principal Financial Officer)

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Panacea Life Sciences Holdings, Inc. (the “Company”) Form 10-Q for the quarter ended June 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Leslie Buttorff, Chief Executive Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

	1.	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and

	2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 15, 2023

/s/ Leslie Buttorff
Leslie Buttorff
Chief Executive Officer and Chief Financial Officer
(Principal Executive Officer and Principal Financial Officer)

Cover - shares	6 Months Ended
Cover - shares	Jun. 30, 2023	Aug. 02, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2023
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-38190
Entity Registrant Name	Panacea Life Sciences Holdings, Inc
Entity Central Index Key	0001552189
Entity Tax Identification Number	27-1085858
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	5910 S University Blvd
Entity Address, Address Line Two	C18-193
Entity Address, City or Town	Greenwood Village
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80121
City Area Code	800
Local Phone Number	985-0515
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		17,645,352

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
CURRENT ASSETS:
Cash and cash equivalents	$ 8,190	$ 6,951
Accounts receivable, net	272,090	206,127
Other receivables, related party	500,000	500,000
Inventory	4,357,733	4,448,725
Marketable securities related party	460,388	1,107,362
Prepaid expenses and other current assets	149,295	113,098
TOTAL CURRENT ASSETS	5,747,696	6,382,263
Operating lease right-of-use asset, net, related party	3,062,090	3,242,381
Property and equipment, net	6,855,283	7,675,995
Goodwill	2,188,810	2,188,810
TOTAL ASSETS	17,853,879	19,489,449
CURRENT LIABILITIES:
Accounts payable and accrued expenses	3,677,546	2,666,076
Operating lease liability, current portion, related party	2,325,808	2,090,271
Note payable-current, related party	10,829,779	9,871,803
Convertible note payable, net	115,000	346,671
Paycheck protection loan, SBA Loan	99,100	99,100
TOTAL CURRENT LIABILITIES:	17,047,233	15,073,921
Operating lease liability, long-term portion, related party	2,800,766	2,987,208
Other long-term liabilities, related party	3,572,864	3,572,864
TOTAL LIABILITIES	23,420,863	21,633,993
Commitments and contingencies
STOCKHOLDERS’ EQUITY
Common Stock: $0.0001 Par Value, 650,000,000 shares authorized; 17,645,352 and 14,965,317 shares issued and outstanding on June 30, 2023 and December 31, 2022 respectively.	1,765	1,497
Additional paid in capital	23,993,533	23,760,704
Accumulated deficit	(29,563,134)	(25,907,597)
TOTAL STOCKHOLDERS’ EQUITY	(5,566,984)	(2,144,544)
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	17,853,879	19,489,449
Series A Preferred Stock [Member]
STOCKHOLDERS’ EQUITY
Preferred Stock, Value
Series B-1 preferred stock [Member]
STOCKHOLDERS’ EQUITY
Preferred Stock, Value	150	150
Series B-2 preferred stock [Member]
STOCKHOLDERS’ EQUITY
Preferred Stock, Value	600	600
Series C Preferred Stock [Member]
STOCKHOLDERS’ EQUITY
Preferred Stock, Value	100	100
Series C-1 Preferred Stock [Member]
STOCKHOLDERS’ EQUITY
Preferred Stock, Value	1	1
Series C-2 preferred stock [Member]
STOCKHOLDERS’ EQUITY
Preferred Stock, Value
Series D Preferred Stock [Member]
STOCKHOLDERS’ EQUITY
Preferred Stock, Value	$ 1	$ 1

Condensed Consolidated Balance Sheets	Jun. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Other Receivable, after Allowance for Credit Loss, Current, Related Party, Type [Extensible Enumeration]	Related Party [Member]	Related Party [Member]
Notes Payable, Current, Related Party, Type [Extensible Enumeration]	Related Party [Member]	Related Party [Member]
Other Liability, Noncurrent, Related Party, Type [Extensible Enumeration]	Related Party [Member]	Related Party [Member]

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Preferred stock, par value	$ 0.0001
Preferred stock, shares designated	50,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	650,000,000	650,000,000
Common stock, shares issued	17,645,352	14,965,317
Common stock, shares outstanding	17,645,352	14,965,317
Series A Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares designated	1,000	1,000
Preferred stock, shares issued	0	350
Preferred stock, shares outstanding	0	350
Series B-1 preferred stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares designated	32,000,000	32,000,000
Preferred stock, shares issued	1,500,000	1,500,000
Preferred stock, shares outstanding	1,500,000	1,500,000
Series B-2 preferred stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares designated	6,000,000	6,000,000
Preferred stock, shares issued	6,000,000	6,000,000
Preferred stock, shares outstanding	6,000,000	6,000,000
Series C Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares designated	1,000,000	1,000,000
Preferred stock, shares issued	1,000,000	1,000,000
Preferred stock, shares outstanding	1,000,000	1,000,000
Series C-1 Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares designated	10,000	10,000
Preferred stock, shares issued	10,000	10,000
Preferred stock, shares outstanding	10,000	10,000
Series C-2 preferred stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares designated	100	0
Preferred stock, shares issued	100	0
Preferred stock, shares outstanding	100	0
Series D Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares designated	10,000	10,000
Preferred stock, shares issued	10,000	10,000
Preferred stock, shares outstanding	10,000	10,000

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
REVENUE	$ 399,128	$ 469,472	$ 1,076,609	$ 935,946
COST OF SALES	196,314	331,500	648,186	697,591
GROSS PROFIT	202,814	137,972	428,423	238,355
OPERATING EXPENSES
Production related operating expenses	1,131,711	1,173,296	2,399,870	2,461,111
General and administrative expenses	145,213	204,678	392,626	665,230
TOTAL OPERATING EXPENSES	1,276,924	1,377,974	2,792,496	3,126,341
LOSS FROM OPERATIONS	(1,074,110)	(1,240,002)	(2,364,073)	(2,887,986)
OTHER INCOME (EXPENSES)
Interest expense	(366,944)	(569,985)	(747,101)	(1,071,280)
Unrealized gain (loss) on marketable securities, net	(464,719)	(260,273)	(646,974)	(1,205,077)
Realized gain on sale of securities		22,816		22,816
Other income (loss)		27,598		27,598
Employer retention credit				253,791
Rental Income	41,531	58,045	101,863	116,091
Gain on extinguishment of debt			748
TOTAL OTHER INCOME (EXPENSE)	(790,132)	(721,799)	(1,291,464)	(1,856,061)
INCOME (LOSS) BEFORE INCOME TAXES	(1,864,242)	(1,961,801)	(3,655,537)	(4,744,047)
TAXES
NET INCOME (LOSS)	$ (1,864,242)	$ (1,961,801)	$ (3,655,537)	$ (4,744,047)
Per-share data
Basic loss per share	$ (0.11)	$ (0.13)	$ (0.21)	$ (0.32)
Diluted loss per share	$ (0.11)	$ (0.13)	$ (0.21)	$ (0.32)
Weighted average number of common shares outstanding, basic	17,645,352	14,965,317	17,645,352	14,965,317
Weighted average number of common shares outstanding, diluted	17,645,352	14,965,317	17,645,352	14,965,317

Condensed Consolidated Statements of Stockholders' (Deficit) Equity (Unaudited) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2021	$ 853	$ 1,407	$ 23,865,155	$ (16,765,013)	$ 7,102,402
Beginning balance, shares at Dec. 31, 2021	8,530,350	14,073,708
Issuance of common shares for services		$ 6	54,994		55,000
Issuance of common shares for services, shares		57,278
Net Income (Loss)				(4,744,047)	(4,744,047)
Shares issued in respect of the merger		$ 83	(83)
Shares issued in respect of the merger, shares		834,331
Conversion of Series A Preferred to convertible debt and warrants			(159,362)		(159,362)
Conversion of Series A Preferred to convertible debt and warrants, shares	(350)
Ending balance, value at Jun. 30, 2022	$ 853	$ 1,497	23,760,704	(21,509,060)	2,253,993
Ending balance, shares at Jun. 30, 2022	8,530,000	14,965,317
Beginning balance, value at Mar. 31, 2022	$ 853	$ 1,476	23,725,724	(19,547,259)	4,180,794
Beginning balance, shares at Mar. 31, 2022	8,530,000	14,762,342
Issuance of common shares for services		$ 5	34,955		35,000
Issuance of common shares for services, shares		48,338
Net Income (Loss)				(1,961,801)	(1,961,801)
Shares issued for acquisition		$ 15	(15)
Shares issued for acquisition, shares		154,637
Ending balance, value at Jun. 30, 2022	$ 853	$ 1,497	23,760,704	(21,509,060)	2,253,993
Ending balance, shares at Jun. 30, 2022	8,530,000	14,965,317
Beginning balance, value at Dec. 31, 2022	$ 853	$ 1,497	23,760,704	(25,907,597)	(2,144,544)
Beginning balance, shares at Dec. 31, 2022	8,530,000	14,965,317
Sale of shares to investors		$ 46	74,955		75,000
Sale of shares to investors, shares		454,545
Issuance of common shares for services		$ 28	23,069		23,097
Issuance of common shares for services, shares		275,490
Issuance of restricted shares to employees		$ 141	(141)
Issuance of restricted shares to employees, shares		1,410,000
Shares issued in settlement of convertible note		$ 54	134,946		135,000
Shares issued in settlement of convertible note, shares		540,000
Net Income (Loss)				(3,655,537)	(3,655,537)
Conversion of Series A Preferred to convertible debt and warrants, shares		730,035
Ending balance, value at Jun. 30, 2023	$ 853	$ 1,765	23,993,532	(29,563,134)	(5,566,984)
Ending balance, shares at Jun. 30, 2023	8,530,000	17,645,352
Beginning balance, value at Mar. 31, 2023	$ 853	$ 1,550	23,895,650	(27,698,892)	(3,800,839)
Beginning balance, shares at Mar. 31, 2023	8,530,350	15,505,317
Sale of shares to investors		$ 46	74,955		75,000
Sale of shares to investors, shares		454,545
Issuance of common shares for services		$ 28	23,069		23,097
Issuance of common shares for services, shares		275,490
Issuance of restricted shares to employees		$ 141	(141)
Issuance of restricted shares to employees, shares		1,410,000
Net Income (Loss)				(1,864,242)	(1,864,242)
Conversion of Series A Preferred to convertible debt and warrants, shares		730,035
Ending balance, value at Jun. 30, 2023	$ 853	$ 1,765	$ 23,993,532	$ (29,563,134)	$ (5,566,984)
Ending balance, shares at Jun. 30, 2023	8,530,000	17,645,352

Statements of Cash Flows - USD ($)	6 Months Ended
Statements of Cash Flows - USD ($)	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities
Net income (loss)	$ (3,655,537)	$ (4,744,047)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation	845,282	818,586
Realized gain on sale of securities		(22,816)
Unrealized (gain)/loss on marketable securities	646,974	1,205,077
Non cash settlement of convertible note and accrued interest	74,999
Amortization of intangible assets		30,700
Amortization of debt discount and non-cash interest expense	38,329	568,219
Changes in operating assets and liabilities
Accounts receivable	(65,963)	24,945
Inventory	90,992	(216,202)
Prepaid expense and other assets	(36,197)	(41,823)
Accounts payable and accrued expenses	1,034,568	982,474
Operating lease liability, net	229,386	229,387
Net cash used in operating activities	(797,167)	(1,165,500)
Cash flows from investing activities
Proceeds from sale of marketable securities		46,832
Net fixed asset acquisitions	(24,570)	(17,604)
Net Cash provided by (used in) investing activities	(24,570)	29,228
Cash flows from financing activities
Repayment of notes payable	(135,000)
Payments of principal on notes payable	(118,000)	(540,848)
Proceeds from Notes payable - related party	1,075,976	1,693,875
Cash provided by financing activities	822,976	1,153,027
Net increase (decrease) in Cash and Cash Equivalents	1,239	16,755
Cash and Cash Equivalents, Beginning of Period	6,951	19,774
Cash and Cash Equivalents, End of Period	8,190	36,529
Supplemental Disclosure of Cash Flow Information
Cash paid for income taxes during the year
Interest payments during the year
Noncash investing and financing activity
Conversion of Preferred A shares to Note Payable		385,000
Issuance of Common Stock for services		55,000
Capitalized assets purchased on account - related party		$ 168,578

NATURE OF ORGANIZATION

6 Months Ended

Jun. 30, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

NATURE OF ORGANIZATION

NOTE 1 - NATURE OF ORGANIZATION

Organization and Business Description

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

6 Months Ended

Jun. 30, 2023

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation and principles of consolidation

The Company’s consolidated financial statements include the financial statements of Panacea Life Sciences, Inc., a wholly owned subsidiary acquired on June 30, 2021.

Going concern

Use of Estimates

Cash and Cash Equivalents

Accounts Receivable

Inventory

Marketable securities

Fair Value Measurements

	●	Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.

	●	Level 2—Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly.

	●	Level 3—Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

The following table shows, by level within the fair value hierarchy, the Company’s assets and liabilities at fair value on a recurring basis as of June 30, 2023, and December 31, 2022:

	June 30, 2023								December 31, 2022
	Total		Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3
Marketable securities	$	460,388	$	460,388	$	-		-	$	1,107,362	$	1,107,362	$	-	$	-
Total	$	460,388	$	460,388	$	-	$	-	$	1,107,362	$	1,107,362	$	-	$	-

The following table is a schedule of the Company’s marketable securities. The following table is schedule of the Company’s marketable securities:

SCHEDULE OF MARKETABLE SECURITIES

	June 30, 2023
Balance at beginning of year	$	1,107,362
Unrealized loss on marketable securities, net		(646,974	)
Balance at end of period	$	460,388

As of June 30, 2023, the Company has no liabilities that are re-measured at fair value.

Property and Equipment

Intangible Assets and Goodwill

The following table is a schedule of the Company’s intangible assets and goodwill:

		Estimated Life
Goodwill from Phoenix Acquisition		Tested Yearly for Impairment
Intangibles – Formulations		5 Years

		June 30, 2023				December 31, 2022
Goodwill		$	2,188,810			$	2,188,810

Leases

Revenue Recognition

The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers.

The following table shows the Company’s advanced customer payments:

	June 30, 2023		December 31, 2022
Balance, beginning of period	$	368,065	$	24,585
Payments received for unearned revenue		214,498		412,891
Revenue earned		252,064		69,411

Balance, end of period	$	330,499	$	368,065

The Company also has recorded other income related to rental income it receives from leasing out space in the laboratory it occupies.

Shipping and Handling Costs

Advertising & Marketing

Segment Information

Stock-Based Compensation

Earnings per Share

The following financial instruments were not included in the diluted loss per share calculation for the six months ended June 30, 2023 and 2022 because their effect was anti-dilutive:

	2023		2022
	For the six months ended June 30,
	2023		2022
Options to purchase common stock		551,854		277,705
Warrants to purchase common stock		1,117,092		1,117,092
Series B-1 Convertible Preferred		6,679		6,679
Series B-2 Convertible Preferred		26,786		26,786
Series C Convertible Preferred		2,289,220		2,289,220
Series C-1 Convertible Preferred		1,064,908		1,064,908
Series D Convertible Preferred		1,628,126		1,628,126
Convertible Notes		-		-
Total		6,684,665		6,410,516

Income Taxes

Recently Issued Accounting Standards

The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

PROPERTY, EQUIPMENT, NET OF ACCUMULATED DEPRECIATION

6 Months Ended

Jun. 30, 2023

Property, Plant and Equipment [Abstract]

PROPERTY, EQUIPMENT, NET OF ACCUMULATED DEPRECIATION

NOTE 3 – PROPERTY, EQUIPMENT, NET OF ACCUMULATED DEPRECIATION

		Estimated Life
Computers and technological assets		3 – 5 Years
Furniture and fixtures		3 – 5 Years
Machinery and equipment		5 – 10 Years
Leasehold improvement		10 Years

Property and equipment, net consists of the following:

SCHEDULE OF PROPERTY AND EQUIPMENT

	June 30, 2023			December 31, 2022
Computers and technological assets	$	3,776,320		$	3,776,320
Furniture and fixtures		55,950			55,950
Machinery and equipment		7,790,036			7,765,466
Land		92,222			92,222
Leasehold improvements		1,508,915			1,508,915
Total		13,223,443			13,198,873
Less accumulated depreciation		(6,368,160	)		(5,522,878	)
Total property and equipment, net	$	6,855,283		$	7,675,995

Depreciation expenses for the three and six month periods ended June 30, 2023 and 2022 were $422,728, 845,282, and 409,895, $818,586 respectively.

INVENTORY

6 Months Ended

Jun. 30, 2023

Inventory Disclosure [Abstract]

INVENTORY

NOTE 4 - INVENTORY

Inventory consists of the following components:

SCHEDULE OF INVENTORY

	June 30, 2023		December 31, 2022
Raw Materials	$	964,317	$	870,530
Semi-Finished		1,771,177		1,863,501
Finished Goods		1,598,280		1,694,574
Packaging		23,959		20,120
Trading				0
Total	$	4,357,733	$	4,448,725

OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES – RELATED PARTY

6 Months Ended

Jun. 30, 2023

Operating Lease Right-of-use Assets And Operating Lease Liabilities Related Party

OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES – RELATED PARTY

NOTE 5 –OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES – RELATED PARTY

Right of Use

Below is a summary of our right of use assets and liabilities as of June 30, 2023, and December 31, 2022:

	June 30, 2023			December 31, 2022
Right-of-use assets	$	3,062,090		$	3,242,381

Present value of operating lease liabilities	$	3,168,620		$	3,347,331
Less: Long-term portion of operating lease liability		(2,800,766	)		(2,987,208	)
Short-term portion of operating lease liability		367,854			360,123
Unpaid balances		1,957,947			1,730,136
Total short-term lease liability obligations	$	2,325,801		$	2,090,259
Weighted-average remaining lease term (Ends December 31, 2030)		7.5 years			8 years

Weighted-average discount rate					3.0	%

Approximate future minimum lease payments for our right of use assets over the remaining lease periods as of June 30, 2023, are as follows:


2023		227,811
2024		460,178
2025		464,780
2026		469,427
2027		474,122
Thereafter		1,451,002
Total undiscounted operating lease payments		3,547,320
Less: Imputed interest		(378,700	)
Present value of operating lease liabilities	$	3,168,620

NOTES PAYABLE

6 Months Ended

Jun. 30, 2023

Debt Disclosure [Abstract]

NOTES PAYABLE

NOTE 6 – NOTES PAYABLE

Convertible Note Payable

Paycheck Protection Program Funding U.S. Small Business Administration Loan

Notes payable – related party and other liability

Below is a summary of our notes payable as of June 30, 2023 and December 31, 2022:

SCHEDULE OF NOTES PAYABLE RELATED PARTY

	June 30, 2023		December 31, 2022
J&N Note	$	4,062,713	$	4,062,713
CEO Notes (Initial note of $1,685,685 and line of credit)		6,767,066		5,809,090
Total related party notes	$	10,829,779	$	9,871,803

Other long-term liabilities, related party

SCHEDULE OF NOTES PAYABLE

	June 30, 2023		December 31, 2022
Other long-term liabilities, related party
Fixed Asset Loan	$	3,059,474	$	3,059,474
J&N Building Loan		513,390		513,390
Total	$	3,572,864	$	3,572,864

STOCKHOLDERS’ EQUITY

6 Months Ended

Jun. 30, 2023

Equity [Abstract]

STOCKHOLDERS’ EQUITY

NOTE 7 - STOCKHOLDERS’ EQUITY

Common stock

The Company’s authorized common stock consists of 650,000,000 shares with a par value of $0.0001 per share.

Common stock options

Stock Option Plan

fully vested options and a total of 551,854 allocated.

Stock Options

A summary of the stock option activity is presented below:

SCHEDULE OF STOCK OPTIONS

	Options Outstanding as of June 30, 2023
					Weighted
	Number of		Weighted		Average
	Shares		Average		Remaining
	Subject		Exercise		Contractual		Aggregate
	to		Price Per		Life		Intrinsic
	Options		Share		(in years)		Value

Balance on December 31, 2022		346,854	$	2.80		3.57	$	-
Options granted		205,000		0.21		-		-
Options exercised		-		-		-		-
Options canceled / expired		-		-		-		-
Balance at June 30, 2023		551,854	$	1.84		2.94	$	-

Vested and exercisable on June 30, 2023		551,854	$	1.84		2.94	$	-

Stock Warrants

The Company’s outstanding warrants as of June 30, 2023, are summarized as follows, and all were exercisable at that date.

SCHEDULE OF WARRANTS OUTSTANDING

	Warrants Outstanding as of June 30, 2023
					Weighted
	Number of		Weighted		Average
	Shares		Average		Remaining
	Subject		Exercise		Contractual		Aggregate
	to		Price Per		Life		Intrinsic
	Warrants		Share		(in years)		Value

Balance on December 31, 2022		1,117,092	$	2.02		4.05		-
Warrants granted		-		-		-		-
Warrants exercised		-		-		-		-
Warrants canceled / expired		-		-		-		-
Balance on June 30, 2023		1,117,092	$	2.02		3.56	$	-

Vested and exercisable on June 30, 2023		1,117,092	$	2.02		3.56	$	-

As of June 30, 2022, the outstanding warrants have no intrinsic value.

Restricted Stock

SUMMARY OF RESTRICTED STOCK

Restricted Stock

Common Stock

Balance on December 31, 2022

107,993

Balance on June 30, 2023

1,793,483

As of June 30, 2023, there were no unamortized or unvested stock-based compensation costs related to restricted share arrangements.

Preferred Stock

The Company’s authorized preferred stock consists of 50,000,000 shares with a par value of $0.0001. There are no new activities related to preferred stock.

COMMITMENTS AND CONTINGENCIES

6 Months Ended

Jun. 30, 2023

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 8 - COMMITMENTS AND CONTINGENCIES

Legal Matters

Concentrations

The Company has no contingencies, material commitments, or purchase obligations or sales obligations.

RELATED PARTY TRANSACTIONS

6 Months Ended

Jun. 30, 2023

RELATED PARTY TRANSACTIONS

NOTE 9 - RELATED PARTY TRANSACTIONS

Notes Payable and Accrued Interest – Related Parties

For information on related party loans to the Company and other related party transactions, see Notes 5 and 6, Operating Lease and Notes Payable.

The accrued interest and interest expenses recorded for related party loans are shown below.

	June 30, 2023		December 31, 2022
Accrued Interest
Related party loan- J&N Real Estate	$	1,095,854	$	796,891
Related party loan-CEO loan		371,510		271,585
Related party loan – Line of credit		592,752		282,869
Accrued Interest		592,752		282,869

	Three months ended		Six months ended		Three months ended		Six months ended
	June 30, 2023		June 30, 2023		June 30, 2022		June 30, 2022
Interest Expense
Related party loan- J&N Real Estate	$	151,713	$	298,964	$	134,637	$	265,315
Related party loan-CEO loan		50,584		99,925		45,790		90,453
Related party loan – Line of Credit		164,646		309,883		51,700		81,835
Interest Expense		164,646		309,883		51,700		81,835

Other

The Company continues to hold 1,188,000 shares of XXII stock which is available for sale.

SUBSEQUENT EVENTS

6 Months Ended

Jun. 30, 2023

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 10– SUBSEQUENT EVENTS

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

6 Months Ended

Jun. 30, 2023

Accounting Policies [Abstract]

Basis of presentation and principles of consolidation

Basis of presentation and principles of consolidation

The Company’s consolidated financial statements include the financial statements of Panacea Life Sciences, Inc., a wholly owned subsidiary acquired on June 30, 2021.

Going concern

Going concern

Use of Estimates

Use of Estimates

Cash and Cash Equivalents

Cash and Cash Equivalents

Accounts Receivable

Accounts Receivable

Inventory

Inventory

Marketable securities

Marketable securities

Fair Value Measurements

Fair Value Measurements

	●	Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.

	●	Level 2—Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly.

	●	Level 3—Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

The following table shows, by level within the fair value hierarchy, the Company’s assets and liabilities at fair value on a recurring basis as of June 30, 2023, and December 31, 2022:

	June 30, 2023								December 31, 2022
	Total		Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3
Marketable securities	$	460,388	$	460,388	$	-		-	$	1,107,362	$	1,107,362	$	-	$	-
Total	$	460,388	$	460,388	$	-	$	-	$	1,107,362	$	1,107,362	$	-	$	-

The following table is a schedule of the Company’s marketable securities. The following table is schedule of the Company’s marketable securities:

SCHEDULE OF MARKETABLE SECURITIES

	June 30, 2023
Balance at beginning of year	$	1,107,362
Unrealized loss on marketable securities, net		(646,974	)
Balance at end of period	$	460,388

As of June 30, 2023, the Company has no liabilities that are re-measured at fair value.

Property and Equipment

Property and Equipment

Intangible Assets and Goodwill

Intangible Assets and Goodwill

The following table is a schedule of the Company’s intangible assets and goodwill:

		Estimated Life
Goodwill from Phoenix Acquisition		Tested Yearly for Impairment
Intangibles – Formulations		5 Years

		June 30, 2023				December 31, 2022
Goodwill		$	2,188,810			$	2,188,810

Leases

Leases

Revenue Recognition

Revenue Recognition

The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers.

The following table shows the Company’s advanced customer payments:

	June 30, 2023		December 31, 2022
Balance, beginning of period	$	368,065	$	24,585
Payments received for unearned revenue		214,498		412,891
Revenue earned		252,064		69,411

Balance, end of period	$	330,499	$	368,065

The Company also has recorded other income related to rental income it receives from leasing out space in the laboratory it occupies.

Shipping and Handling Costs

Shipping and Handling Costs

Advertising & Marketing

Advertising & Marketing

Segment Information

Segment Information

Stock-Based Compensation

Stock-Based Compensation

Earnings per Share

Earnings per Share

The following financial instruments were not included in the diluted loss per share calculation for the six months ended June 30, 2023 and 2022 because their effect was anti-dilutive:

	2023		2022
	For the six months ended June 30,
	2023		2022
Options to purchase common stock		551,854		277,705
Warrants to purchase common stock		1,117,092		1,117,092
Series B-1 Convertible Preferred		6,679		6,679
Series B-2 Convertible Preferred		26,786		26,786
Series C Convertible Preferred		2,289,220		2,289,220
Series C-1 Convertible Preferred		1,064,908		1,064,908
Series D Convertible Preferred		1,628,126		1,628,126
Convertible Notes		-		-
Total		6,684,665		6,410,516

Income Taxes

Income Taxes

Recently Issued Accounting Standards

Recently Issued Accounting Standards

The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

6 Months Ended

Jun. 30, 2023

Accounting Policies [Abstract]

SCHEDULE OF FAIR VALUE ASSETS MEASURED ON RECURRING BASIS

The following table shows, by level within the fair value hierarchy, the Company’s assets and liabilities at fair value on a recurring basis as of June 30, 2023, and December 31, 2022:

	June 30, 2023								December 31, 2022
	Total		Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3
Marketable securities	$	460,388	$	460,388	$	-		-	$	1,107,362	$	1,107,362	$	-	$	-
Total	$	460,388	$	460,388	$	-	$	-	$	1,107,362	$	1,107,362	$	-	$	-

SCHEDULE OF MARKETABLE SECURITIES

The following table is a schedule of the Company’s marketable securities. The following table is schedule of the Company’s marketable securities:

SCHEDULE OF MARKETABLE SECURITIES

	June 30, 2023
Balance at beginning of year	$	1,107,362
Unrealized loss on marketable securities, net		(646,974	)
Balance at end of period	$	460,388

SCHEDULE OF INTANGIBLE ASSETS AND GOODWILL

The following table is a schedule of the Company’s intangible assets and goodwill:

		Estimated Life
Goodwill from Phoenix Acquisition		Tested Yearly for Impairment
Intangibles – Formulations		5 Years

		June 30, 2023				December 31, 2022
Goodwill		$	2,188,810			$	2,188,810

SCHEDULE OF REVENUE FROM CONTRACT WITH CUSTOMER

The following table shows the Company’s advanced customer payments:

	June 30, 2023		December 31, 2022
Balance, beginning of period	$	368,065	$	24,585
Payments received for unearned revenue		214,498		412,891
Revenue earned		252,064		69,411

Balance, end of period	$	330,499	$	368,065

SCHEDULE OF ANTI-DILUTIVE DILUTED LOSS PER SHARE

The following financial instruments were not included in the diluted loss per share calculation for the six months ended June 30, 2023 and 2022 because their effect was anti-dilutive:

	2023		2022
	For the six months ended June 30,
	2023		2022
Options to purchase common stock		551,854		277,705
Warrants to purchase common stock		1,117,092		1,117,092
Series B-1 Convertible Preferred		6,679		6,679
Series B-2 Convertible Preferred		26,786		26,786
Series C Convertible Preferred		2,289,220		2,289,220
Series C-1 Convertible Preferred		1,064,908		1,064,908
Series D Convertible Preferred		1,628,126		1,628,126
Convertible Notes		-		-
Total		6,684,665		6,410,516

PROPERTY, EQUIPMENT, NET OF ACCUMULATED DEPRECIATION (Tables)

6 Months Ended

Jun. 30, 2023

Property, Plant and Equipment [Abstract]

SCHEDULE OF PROPERTY PLANT AND EQUIPMENT USEFUL LIVES

		Estimated Life
Computers and technological assets		3 – 5 Years
Furniture and fixtures		3 – 5 Years
Machinery and equipment		5 – 10 Years
Leasehold improvement		10 Years

SCHEDULE OF PROPERTY AND EQUIPMENT

Property and equipment, net consists of the following:

SCHEDULE OF PROPERTY AND EQUIPMENT

	June 30, 2023			December 31, 2022
Computers and technological assets	$	3,776,320		$	3,776,320
Furniture and fixtures		55,950			55,950
Machinery and equipment		7,790,036			7,765,466
Land		92,222			92,222
Leasehold improvements		1,508,915			1,508,915
Total		13,223,443			13,198,873
Less accumulated depreciation		(6,368,160	)		(5,522,878	)
Total property and equipment, net	$	6,855,283		$	7,675,995

INVENTORY (Tables)

6 Months Ended

Jun. 30, 2023

Inventory Disclosure [Abstract]

SCHEDULE OF INVENTORY

Inventory consists of the following components:

SCHEDULE OF INVENTORY

	June 30, 2023		December 31, 2022
Raw Materials	$	964,317	$	870,530
Semi-Finished		1,771,177		1,863,501
Finished Goods		1,598,280		1,694,574
Packaging		23,959		20,120
Trading				0
Total	$	4,357,733	$	4,448,725

OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES – RELATED PARTY (Tables)

6 Months Ended

Jun. 30, 2023

Operating Lease Right-of-use Assets And Operating Lease Liabilities Related Party

SCHEDULE OF RIGHT OF USE ASSET AND LIABILITY

	June 30, 2023			December 31, 2022
Right-of-use assets	$	3,062,090		$	3,242,381

Present value of operating lease liabilities	$	3,168,620		$	3,347,331
Less: Long-term portion of operating lease liability		(2,800,766	)		(2,987,208	)
Short-term portion of operating lease liability		367,854			360,123
Unpaid balances		1,957,947			1,730,136
Total short-term lease liability obligations	$	2,325,801		$	2,090,259
Weighted-average remaining lease term (Ends December 31, 2030)		7.5 years			8 years

Weighted-average discount rate					3.0	%

SCHEDULE OF MATURITY OF OPERATING LEASE LIABILITIES

Approximate future minimum lease payments for our right of use assets over the remaining lease periods as of June 30, 2023, are as follows:


2023		227,811
2024		460,178
2025		464,780
2026		469,427
2027		474,122
Thereafter		1,451,002
Total undiscounted operating lease payments		3,547,320
Less: Imputed interest		(378,700	)
Present value of operating lease liabilities	$	3,168,620

NOTES PAYABLE (Tables)

6 Months Ended

Jun. 30, 2023

Debt Disclosure [Abstract]

SCHEDULE OF NOTES PAYABLE RELATED PARTY

	June 30, 2023		December 31, 2022
J&N Note	$	4,062,713	$	4,062,713
CEO Notes (Initial note of $1,685,685 and line of credit)		6,767,066		5,809,090
Total related party notes	$	10,829,779	$	9,871,803

SCHEDULE OF NOTES PAYABLE

	June 30, 2023		December 31, 2022
Other long-term liabilities, related party
Fixed Asset Loan	$	3,059,474	$	3,059,474
J&N Building Loan		513,390		513,390
Total	$	3,572,864	$	3,572,864

STOCKHOLDERS’ EQUITY (Tables)

6 Months Ended

Jun. 30, 2023

Equity [Abstract]

SCHEDULE OF STOCK OPTIONS

A summary of the stock option activity is presented below:

SCHEDULE OF STOCK OPTIONS

	Options Outstanding as of June 30, 2023
					Weighted
	Number of		Weighted		Average
	Shares		Average		Remaining
	Subject		Exercise		Contractual		Aggregate
	to		Price Per		Life		Intrinsic
	Options		Share		(in years)		Value

Balance on December 31, 2022		346,854	$	2.80		3.57	$	-
Options granted		205,000		0.21		-		-
Options exercised		-		-		-		-
Options canceled / expired		-		-		-		-
Balance at June 30, 2023		551,854	$	1.84		2.94	$	-

Vested and exercisable on June 30, 2023		551,854	$	1.84		2.94	$	-

SCHEDULE OF WARRANTS OUTSTANDING

The Company’s outstanding warrants as of June 30, 2023, are summarized as follows, and all were exercisable at that date.

SCHEDULE OF WARRANTS OUTSTANDING

	Warrants Outstanding as of June 30, 2023
					Weighted
	Number of		Weighted		Average
	Shares		Average		Remaining
	Subject		Exercise		Contractual		Aggregate
	to		Price Per		Life		Intrinsic
	Warrants		Share		(in years)		Value

Balance on December 31, 2022		1,117,092	$	2.02		4.05		-
Warrants granted		-		-		-		-
Warrants exercised		-		-		-		-
Warrants canceled / expired		-		-		-		-
Balance on June 30, 2023		1,117,092	$	2.02		3.56	$	-

Vested and exercisable on June 30, 2023		1,117,092	$	2.02		3.56	$	-

SUMMARY OF RESTRICTED STOCK

Restricted Stock

Common Stock

Balance on December 31, 2022

107,993

Balance on June 30, 2023

1,793,483

RELATED PARTY TRANSACTIONS (Tables)

6 Months Ended

Jun. 30, 2023

The accrued interest and interest expenses recorded for related party loans are shown below.

	June 30, 2023		December 31, 2022
Accrued Interest
Related party loan- J&N Real Estate	$	1,095,854	$	796,891
Related party loan-CEO loan		371,510		271,585
Related party loan – Line of credit		592,752		282,869
Accrued Interest		592,752		282,869

	Three months ended		Six months ended		Three months ended		Six months ended
	June 30, 2023		June 30, 2023		June 30, 2022		June 30, 2022
Interest Expense
Related party loan- J&N Real Estate	$	151,713	$	298,964	$	134,637	$	265,315
Related party loan-CEO loan		50,584		99,925		45,790		90,453
Related party loan – Line of Credit		164,646		309,883		51,700		81,835
Interest Expense		164,646		309,883		51,700		81,835

NATURE OF ORGANIZATION (Details Narrative)	Jun. 30, 2023 ft²
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Area square foot	51,000

SCHEDULE OF FAIR VALUE ASSETS MEASURED ON RECURRING BASIS (Details) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Marketable securities	$ 460,388	$ 1,107,362
Fair Value, Inputs, Level 1 [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Marketable securities	460,388	1,107,362
Fair Value, Inputs, Level 2 [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Marketable securities
Fair Value, Inputs, Level 3 [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Marketable securities
Marketable Securities [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Marketable securities	460,388	1,107,362
Marketable Securities [Member] \| Fair Value, Inputs, Level 1 [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Marketable securities	460,388	1,107,362
Marketable Securities [Member] \| Fair Value, Inputs, Level 2 [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Marketable securities
Marketable Securities [Member] \| Fair Value, Inputs, Level 3 [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Marketable securities

SCHEDULE OF MARKETABLE SECURITIES (Details) - USD ($)	3 Months Ended		6 Months Ended
SCHEDULE OF MARKETABLE SECURITIES (Details) - USD ($)	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Accounting Policies [Abstract]
Balance at beginning of year			$ 1,107,362
Unrealized loss on marketable securities, net	$ (464,719)	$ (260,273)	(646,974)	$ (1,205,077)
Balance at end of period	$ 460,388		$ 460,388

SCHEDULE OF INTANGIBLE ASSETS AND GOODWILL (Details) - USD ($)	6 Months Ended
	Jun. 30, 2023	Dec. 31, 2022	Oct. 31, 2017
Restructuring Cost and Reserve [Line Items]
Finite-lived intangible asset, useful life	5 years
Goodwill	$ 2,188,810	$ 2,188,810
Phoenix Life Sciences, Inc. [Member]
Restructuring Cost and Reserve [Line Items]
Goodwill from phoenix acquisition	Tested Yearly for Impairment
Goodwill			$ 2,189,000

SCHEDULE OF REVENUE FROM CONTRACT WITH CUSTOMER (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Balance, beginning of period	$ 368,065	$ 24,585
Payments received for unearned revenue	214,498	412,891
Revenue earned	252,064	69,411
Balance, end of period	$ 330,499	$ 368,065

SCHEDULE OF ANTI-DILUTIVE DILUTED LOSS PER SHARE (Details) - shares	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	6,684,665	6,410,516
Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	551,854	277,705
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,117,092	1,117,092
Series B-1 Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	6,679	6,679
Series B-2 Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	26,786	26,786
Series C Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	2,289,220	2,289,220
Series C-1 Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,064,908	1,064,908
Series D Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,628,126	1,628,126
Convertible Notes Payable [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Oct. 31, 2017
Property, Plant and Equipment [Line Items]
Retained earnings	$ 29,563,134		$ 29,563,134		$ 25,907,597
Cash and liquid stock	465,000		465,000
Common stock value	1,765		1,765		1,497
Notes payable current	10,829,779		10,829,779		9,871,803
Allowance for doubtful accounts			10,000
Allowance for doubtful expense	0		0
Business acquisition, goodwill	2,188,810		2,188,810		2,188,810
Customer advances payments	330,499		330,499		368,065
Shipping and handling costs	32,633	$ 3,782
Advertising expense	14,563	$ 31,312
General and Administrative Expense [Member]
Property, Plant and Equipment [Line Items]
Shipping and handling costs			43,001	$ 17,965
Advertising expense			18,193	$ 98,108
Phoenix Life Sciences, Inc. [Member]
Property, Plant and Equipment [Line Items]
Business acquisition, goodwill						$ 2,189,000
Business acquisition, intangible assets	$ 30,000.000		$ 30,000.000		$ 61,000.000
Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years		3 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	10 years		10 years
Marketable Securities [Member]
Property, Plant and Equipment [Line Items]
Investment owned balance shares	1,188,000		1,188,000
Leslie Buttorff [Member]
Property, Plant and Equipment [Line Items]
Notes payable current	$ 1,624,000		$ 1,624,000
22nd Century Group, Inc [Member]
Property, Plant and Equipment [Line Items]
Common stock other shares outstanding	1,188,000		1,188,000
Common stock value	$ 457,000		$ 457,000
Quintel MC Inc [Member]
Property, Plant and Equipment [Line Items]
Notes payable current	$ 4,063,000.000		$ 4,063,000.000

SCHEDULE OF PROPERTY PLANT AND EQUIPMENT USEFUL LIVES (Details)	Jun. 30, 2023
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	10 years
Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	3 years
Minimum [Member] \| Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	3 years
Minimum [Member] \| Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	3 years
Minimum [Member] \| Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	5 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	10 years
Maximum [Member] \| Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	5 years
Maximum [Member] \| Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	5 years
Maximum [Member] \| Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	10 years

SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Total	$ 13,223,443	$ 13,198,873
Less accumulated depreciation	(6,368,160)	(5,522,878)
Total property and equipment, net	6,855,283	7,675,995
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	3,776,320	3,776,320
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Total	55,950	55,950
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	7,790,036	7,765,466
Land [Member]
Property, Plant and Equipment [Line Items]
Total	92,222	92,222
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total	$ 1,508,915	$ 1,508,915

PROPERTY, EQUIPMENT, NET OF ACCUMULATED DEPRECIATION (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Depreciation expenses	$ 422,728	$ 409,895	$ 845,282	$ 818,586

SCHEDULE OF INVENTORY (Details) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Raw Materials	$ 964,317	$ 870,530
Semi-Finished	1,771,177	1,863,501
Finished Goods	1,598,280	1,694,574
Packaging	23,959	20,120
Trading		0
Total	$ 4,357,733	$ 4,448,725

SCHEDULE OF RIGHT OF USE ASSET AND LIABILITY (Details) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Operating Lease Right-of-use Assets And Operating Lease Liabilities Related Party
Right-of-use assets	$ 3,062,090	$ 3,242,381
Present value of operating lease liabilities	3,168,620	3,347,331
Less: Long-term portion of operating lease liability	(2,800,766)	(2,987,208)
Short-term portion of operating lease liability	367,854	360,123
Unpaid balances	1,957,947	1,730,136
Total short-term lease liability obligations	$ 2,325,801	$ 2,090,259
Weighted-average remaining lease term (Ends December 31, 2030)	7 years 6 months	8 years
Weighted-average discount rate		3.00%

SCHEDULE OF MATURITY OF OPERATING LEASE LIABILITIES (Details) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Operating Lease Right-of-use Assets And Operating Lease Liabilities Related Party
2023	$ 227,811
2024	460,178
2025	464,780
2026	469,427
2027	474,122
Thereafter	1,451,002
Total undiscounted operating lease payments	3,547,320
Less: Imputed interest	(378,700)
Present value of operating lease liabilities	$ 3,168,620	$ 3,347,331

OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES – RELATED PARTY (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Lease expiring			Dec. 31, 2030
Present value of operating lease liabilities	$ 3,168,620		$ 3,168,620		$ 3,347,331
Lease term	3 years		3 years
Operating lease, cost	$ 114,693	$ 229,386	$ 114,693	$ 229,386
Accounting Standards Update 2016-02 [Member]
Present value of operating lease liabilities	$ 4,595,509		$ 4,595,509

SCHEDULE OF NOTES PAYABLE RELATED PARTY (Details) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Short-Term Debt [Line Items]
Total related party notes	$ 10,829,779	$ 9,871,803
Related Party [Member]
Short-Term Debt [Line Items]
Total related party notes	10,829,779	9,871,803
Quintel Note [Member] \| Related Party [Member]
Short-Term Debt [Line Items]
Total related party notes	4,062,713	4,062,713
CEO Note [Member] \| Related Party [Member]
Short-Term Debt [Line Items]
Total related party notes	$ 6,767,066	$ 5,809,090

SCHEDULE OF NOTES PAYABLE RELATED PARTY (Details) (Parenthetical) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
CEO Note [Member]
Short-Term Debt [Line Items]
Lines of credit	$ 1,685,685	$ 1,685,685

SCHEDULE OF NOTES PAYABLE (Details) - USD ($)	Jun. 30, 2023	Dec. 31, 2022	Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Total	$ 3,572,864	$ 3,572,864
Fixed Asset Loan [Member]
Defined Benefit Plan Disclosure [Line Items]
Total	3,059,474	3,059,474
JN Building Loan [Member]
Defined Benefit Plan Disclosure [Line Items]
Total	$ 513,390	$ 513,390	$ 513,390

NOTES PAYABLE (Details Narrative) - USD ($)				3 Months Ended		6 Months Ended
NOTES PAYABLE (Details Narrative) - USD ($)	Nov. 18, 2021	Jul. 01, 2021	May 28, 2020	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Mar. 31, 2023	Dec. 31, 2022	Mar. 03, 2022	Jun. 30, 2021	Dec. 31, 2020
Short-Term Debt [Line Items]
Common stock, par or stated value per share				$ 0.0001		$ 0.0001			$ 0.0001
Convertible notes payable				$ 115,000		$ 115,000			$ 346,671
Amortization of debt discount and non-cash interest expense						38,329	$ 568,219
Note payable-current, related party				10,829,779		10,829,779			9,871,803
Other long-term liabilities, related party				$ 3,572,864		$ 3,572,864			$ 3,572,864
Fixed Asset Loan [Member]
Short-Term Debt [Line Items]
Interest rate effective percentage									6.00%
Interest rate				6.00%		6.00%			6.00%
Related Party [Member]
Short-Term Debt [Line Items]
Note payable-current, related party				$ 10,829,779		$ 10,829,779			$ 9,871,803
Fixed Asset Loan [Member]
Short-Term Debt [Line Items]
Other long-term liabilities, related party				3,059,474		3,059,474			3,059,474
JN Building Loan [Member]
Short-Term Debt [Line Items]
Other long-term liabilities, related party				513,390		513,390			513,390			$ 513,390
Economic Injury Disaster Loan [Member]
Short-Term Debt [Line Items]
Disaster loan amount					$ 99,100		99,100
Debt principal and interest			$ 483
Accrued interest					$ 2,047		$ 2,047
Quintel Note [Member] \| Related Party [Member]
Short-Term Debt [Line Items]
Note payable-current, related party				$ 4,062,713		4,062,713			$ 4,062,713
Buttorff Note [Member]
Short-Term Debt [Line Items]
Interest rate		10.00%									10.00%
Proceeds from lines of credit		$ 1
Increase in line of credit						$ 5,500,000
Series A Preferred Stock [Member]
Short-Term Debt [Line Items]
Preferred stock, shares issued				0		0			350
US Small Business Administration [Member] \| Notes Payable [Member]
Short-Term Debt [Line Items]
Disaster loan amount			$ 99,100
Interest rate			3.75%
Chief Executive Officer [Member] \| Quintel Note [Member]
Short-Term Debt [Line Items]
Principal amount				$ 4,062,000.000		$ 4,062,000.000
Interest rate				12.00%		12.00%
Chief Executive Officer [Member] \| Quintel Note [Member] \| Related Party [Member]
Short-Term Debt [Line Items]
Note payable-current, related party				$ 1,932,358		$ 1,932,358
Chief Executive Officer [Member] \| Buttorff Note [Member]
Short-Term Debt [Line Items]
Percentage of promissory											10.00%
Quintel Note											$ 1,624,000
Securities Purchase Agreement [Member] \| Lincoln Park Capital Fund LLC [Member]
Short-Term Debt [Line Items]
Interest rate effective percentage	10.00%
Principal amount	$ 1,100,000
Warrant, term	5 years
Class of warrant or rights	785,715
Common stock, par or stated value per share	$ 0.0001
Warrant exercise price	$ 1.40
Convertible notes payable	$ 1,000,000
Debt conversion description	The Warrants contain a 4.99% beneficial ownership limitation pursuant to which neither may be converted or exercised, as applicable, if and to the extent that following such conversion or exercise the holder would beneficially own more than 4.99% of the Company’s outstanding common stock, subject to increase to 9.99% upon 61 days’ prior written notice by the holder
Debt conversion rate	4.99%
Securities Purchase Agreement [Member] \| Lincoln Park Capital Fund LLC [Member] \| Minimum [Member]
Short-Term Debt [Line Items]
Debt conversion rate	4.99%
Securities Purchase Agreement [Member] \| Lincoln Park Capital Fund LLC [Member] \| Maximum [Member]
Short-Term Debt [Line Items]
Debt conversion rate	9.99%
Exchange Agreement [Member] \| Investor [Member]
Short-Term Debt [Line Items]
Interest rate effective percentage										10.00%
Warrant, term										5 years
Class of warrant or rights										275,000
Common stock, par or stated value per share										$ 0.0001
Warrant exercise price					$ 1.40		$ 1.40			$ 1.40
Debt Instrument, Face Amount										$ 385,000
Warrants and rights outstanding				190,638		190,638
Unamortized discount								$ 35,000
Amortization of debt discount and non-cash interest expense				$ 0	$ 56,255	$ 17,309	$ 73,564
Exchange Agreement [Member] \| Investor [Member] \| Series A Preferred Stock [Member]
Short-Term Debt [Line Items]
Preferred stock, shares issued										350

SCHEDULE OF STOCK OPTIONS (Details) - USD ($)	6 Months Ended	12 Months Ended
SCHEDULE OF STOCK OPTIONS (Details) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Equity [Abstract]
Options outstanding, beginning	346,854
Weighted average exercise price per share outstanding, beginning	$ 2.80
Weighted average remaining contractual life outstanding, ending	2 years 11 months 8 days	3 years 6 months 25 days
Aggregate intrinsic value outstanding, warrants outstanding Beginning
Options granted	205,000
Weighted average exercise price per share, options granted	$ 0.21
Options exercised
Weighted average exercise price per share, options exercised
Options canceled/expired
Weighted average exercise price per share, options canceled/expired
Options outstanding, ending	551,854	346,854
eighted average exercise price per share outstanding, ending	$ 1.84	$ 2.80
Aggregate intrinsic value outstanding, warrants outstanding Ending
Options vested and exercisable	551,854
Weighted Average exercise price per share outstanding, vested and exercisable	$ 1.84
Weighted average remaining contractual life outstanding, vested and exercisable	2 years 11 months 8 days
Aggregate intrinsic value outstanding, warrants outstanding vested and exercisable

SCHEDULE OF WARRANTS OUTSTANDING (Details) - USD ($)	6 Months Ended	12 Months Ended
SCHEDULE OF WARRANTS OUTSTANDING (Details) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Equity [Abstract]
Number of Shares, warrants outstanding Beginning	1,117,092
Weighted average exercise price per share, warrants outstanding Beginning	$ 2.02
Weighted average remaining contractual life warrants outstanding	3 years 6 months 21 days	4 years 18 days
Aggregate intrinsic value outstanding, warrants outstanding Beginning
Number of Shares, granted
Weighted average exercise price per share, options granted
Number of Shares, exercised
Weighted average exercise price per share, options exercised
Number of Shares, canceled / expired
Weighted average exercise price per share, options canceled/expired
Number of Shares, warrants outstanding Ending	1,117,092	1,117,092
Weighted average exercise price per share, warrants outstanding Ending	$ 2.02	$ 2.02
Aggregate intrinsic value outstanding, warrants outstanding Ending
Number of Shares, vested and exercisable	1,117,092
Weighted Average exercise price per share, warrants outstanding vested and exercisable	$ 2.02
Weighted average remaining contractual life warrants outstanding vested and exercisable	3 years 6 months 21 days
Aggregate intrinsic value outstanding, warrants outstanding vested and exercisable

SUMMARY OF RESTRICTED STOCK (Details)	Jun. 30, 2023 shares
Equity [Abstract]
Restricted stock, ending balance	107,993
Restricted stock, ending balance	1,793,483

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended	6 Months Ended
STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)	Jun. 30, 2021	Jun. 30, 2023	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022	Mar. 03, 2022	Nov. 18, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, authorized		650,000,000	650,000,000	650,000,000
Common stock, par value		$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized		50,000,000	50,000,000
Preferred stock, par value per share		$ 0.0001	$ 0.0001
Series A Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares issued		0	0	350
Preferred stock, shares authorized		1,000	1,000	1,000
Preferred stock, par value per share		$ 0.0001	$ 0.0001	$ 0.0001
Stock Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants to purchase shares		56,377	56,377
Securities Purchase Agreement [Member] \| Linco ln Park Capital Fund [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, par value							$ 0.0001
Interest rate, effective percentage							10.00%
Carrying amount							$ 1,100,000
Class of warrants							785,715
Exercise price							$ 1.40
Securities Purchase Agreement [Member] \| Linco ln Park Capital Fund [Member] \| Stock Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants purchase price							$ 1,000,000
2021 Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
New issuance of shares	4,049,409
Number of years shares available for grant	10 years
Option vested	346,854
Total option allocated	551,854
Vendor [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock issued			275,490
Investor [Member] \| Exchange Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, par value						$ 0.0001
Interest rate, effective percentage						10.00%
Carrying amount						$ 385,000
Class of warrants						275,000
Exercise price					$ 1.40	$ 1.40
Warrants purchase price		$ 190,638	$ 190,638
Warrants to purchase shares						275,000
Investor [Member] \| Exchange Agreement [Member] \| Series A Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares issued						350
Employees and Directors [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Restricted stock, issued		1,685,490	1,685,490
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock issued in share exchange		730,035	730,035
Common stock issued		454,545	454,545
Restricted stock, issued		1,410,000	1,410,000
Common Stock [Member] \| Investor [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock issued			454,545

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended	6 Months Ended
	Jul. 31, 2023	Jun. 30, 2023	Jun. 30, 2023
Revenue Benchmark [Member] \| Customer Concentration Risk [Member] \| One Customer [Member]
Loss Contingencies [Line Items]
Concentration Risk, Percentage		41.00%	12.00%
Revenue Benchmark [Member] \| Customer Concentration Risk [Member] \| Two Customer [Member]
Loss Contingencies [Line Items]
Concentration Risk, Percentage		15.00%	17.00%
Revenue Benchmark [Member] \| Customer Concentration Risk [Member] \| Three Customer [Member]
Loss Contingencies [Line Items]
Concentration Risk, Percentage			20.00%
Accounts Receivable [Member] \| Customer Concentration Risk [Member] \| Three Customer [Member]
Loss Contingencies [Line Items]
Concentration Risk, Percentage			69.00%
Accounts Receivable [Member] \| Customer Concentration Risk [Member] \| Customer Receivable [Member] \| Minimum [Member]
Loss Contingencies [Line Items]
Concentration Risk, Percentage			23.00%
Accounts Receivable [Member] \| Customer Concentration Risk [Member] \| Customer Receivable [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
Concentration Risk, Percentage			69.00%
Subsequent Event [Member]
Loss Contingencies [Line Items]
Plaintiff value	$ 80,000

SCHEDULE OF RELATED PARTY TRANSACTIONS LOANS (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Related Party Transaction [Line Items]
Accrued Interest	$ 592,752		$ 592,752		$ 282,869
Interest Expense	366,944	$ 569,985	747,101	$ 1,071,280
Related Party Loan J And N Real Estate [Member]
Related Party Transaction [Line Items]
Accrued Interest	1,095,854		1,095,854		796,891
Interest Expense	151,713	134,637	298,964	265,315
Related Party Loan CEO Loan [Member]
Related Party Transaction [Line Items]
Accrued Interest	371,510		371,510		271,585
Interest Expense	50,584	45,790	99,925	90,453
Related Party Loan Line Of Credit [Member]
Related Party Transaction [Line Items]
Accrued Interest	592,752		592,752		$ 282,869
Interest Expense	$ 164,646	$ 51,700	$ 309,883	$ 81,835

RELATED PARTY TRANSACTIONS (Details Narrative)	Jun. 30, 2023 shares
XXII Common Stock [Member]
Number of shares available for grant	1,188,000

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Revenue	$ 399,128	$ 469,472	$ 1,076,609	$ 935,946
Largo, Florida [Member]
Revenue					$ 2,900,000

	Real-time Prices	Level 2
London Stock Exchange
Chi-X Europe
BATS Europe
Aquis Exchange
FTSE Indices
Euronext
New York Stock Exchange
NASDAQ
American Stock Exchange
Dow Jones Indices
Forex
Precious Metal

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

PLSH Panacea Life Sciences Holdings Inc (PK)